WO2007044560A2 - Modulators of atp-binding cassette transporters - Google Patents

Modulators of atp-binding cassette transporters Download PDF

Info

Publication number
WO2007044560A2
WO2007044560A2 PCT/US2006/039220 US2006039220W WO2007044560A2 WO 2007044560 A2 WO2007044560 A2 WO 2007044560A2 US 2006039220 W US2006039220 W US 2006039220W WO 2007044560 A2 WO2007044560 A2 WO 2007044560A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
conr
independently
alkyl
replaced
Prior art date
Application number
PCT/US2006/039220
Other languages
French (fr)
Other versions
WO2007044560A3 (en
Inventor
Sara Hadida Ruah
Anna Hazlewood
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to CA002624683A priority Critical patent/CA2624683A1/en
Priority to EP06825588A priority patent/EP1933831A2/en
Priority to JP2008534730A priority patent/JP2009511494A/en
Priority to AU2006302371A priority patent/AU2006302371A1/en
Publication of WO2007044560A2 publication Critical patent/WO2007044560A2/en
Publication of WO2007044560A3 publication Critical patent/WO2007044560A3/en
Priority to IL190570A priority patent/IL190570A0/en
Priority to NO20082082A priority patent/NO20082082L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to modulators of ATP-Binding Cassette
  • ABC Cystic Fibrosis Transmembrane Conductance Regulator
  • CFTR Cystic Fibrosis Transmembrane Conductance Regulator
  • ABC transporters are a family of membrane transporter proteins that regulate the transport of a wide variety of pharmacological agents, potentially toxic drugs, and xenobiotics, as well as anions.
  • ABC transporters are homologous membrane proteins that bind and use cellular adenosine triphosphate (ATP) for their specific activities. Some of these transporters were discovered as multidrug resistance proteins (like the MDRl-P glycoprotein, or the multidrug resistance protein, MRPl), defending malignant cancer cells against chemotherapeutic agents. To date, 48 ABC Transporters have been identified and grouped into 7 families based on their sequence identity and function.
  • ABC transporters regulate a variety of important physiological roles within the body and provide defense against harmful environmental compounds. Because of this, they represent important potential drug targets for the treatment of diseases associated with defects in the transporter, prevention of drug transport out of the target cell, and intervention in other diseases in which modulation of ABC transporter activity may be beneficial.
  • CFTR cAMP/ATP-mediated anion channel
  • CFTR is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue.
  • CFTR is composed of protein made up of a tandem repeate of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
  • Cystic Fibrosis affects approximately one in every 2,500 infants in the United States. Within the general United States population, up to 10 million people carry a single copy of the defective gene without apparent ill effects. In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung disease.
  • the most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as ⁇ F508-CFTR. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease .
  • CFTR transports a variety of molecules in addition to anions
  • this role represents one element in an important mechanism of transporting ions and water across the epithelium.
  • the other elements include the epithelial Na + channel, ENaC, Na + /2C17K + co-transporter, Na + -K + -ATPaSe pump and the basolateral membrane K + channels, that are responsible for the uptake of chloride into the cell.
  • CFTR activity may be beneficial for other diseases not directly caused by mutations in CFTR, such as secretory diseases and other protein folding diseases mediated by CFTR. These include, but are not limited to, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.
  • COPD chronic obstructive pulmonary disease
  • COPD dry eye disease
  • Sjogren's Syndrome Sjogren's Syndrome
  • COPD is characterized by airflow limitation that is progressive and not fully reversible.
  • the airflow limitation is due to mucus hypersecretion, emphysema, and rbB ⁇ Ihi6lW ⁇ I3bivafbB.
  • S ⁇ rHMlor wild-type CFTR offer a potential treatment of mucus hypersecretion and impaired mucociliary clearance that is common in COPD.
  • increasing anion secretion across CFTR may facilitate fluid transport into the airway surface liquid to hydrate the mucus and optimized periciliary fluid viscosity. This would lead to enhanced mucociliary clearance and a reduction in the symptoms associated with COPD.
  • Dry eye disease is characterized by a decrease in tear aqueous production and abnormal tear film lipid, protein and mucin profiles.
  • causes of dry eye some of which include age, Lasik eye surgery, arthritis, medications, chemical/thermal burns, allergies, and diseases, such as Cystic Fibrosis and Sj ⁇ grens's syndrome.
  • Increasing anion secretion via CFTR would enhance fluid transport from the corneal endothelial cells and secretory glands surrounding the eye to increase corneal hydration. This would help to alleviate the symptoms associated with dry eye disease.
  • Sj ⁇ grens's syndrome is an autoimmune disease in which the immune system attacks moisture-producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut.
  • Symptoms include, dry eye, mouth, and vagina, as well as lung disease.
  • the disease is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymypositis/dermatomyositis. Defective protein trafficking is believed to cause the disease, for which treatment options are limited. Modulators of CFTR activity may hydrate the various organs afflicted by the disease and help to elevate the associated symptoms.
  • ⁇ F508-CFTR prevents the nascent protein from folding correctly, resulting in the inability of this mutant protein to exit the ER, and traffic to the plasma membrane.
  • insufficient amounts of the mature protein are present at the plasma membrane and chloride transport within epithelial tissues is significantly reduced.
  • this cellular phenomenon of defective ER processing of ABC transporters by the ER machinery has been shown to be the underlying basis not only for CF disease, but for a wide range of other isolated and inherited diseases.
  • the diseases associated with the first class of ER malfunction are Cystic fibrosis (due to misfolded ⁇ F508-CFTR as discussed above), Hereditary emphysema (due to al- antitrypsin; non Piz variants), Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing PclSfi ' (Iencyk!,'ii ⁇ Htis"f aiillai ⁇ ipplilcholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses (due to Lysosomal processing enzymes), Sandhof/Tay-Sachs (due to ⁇ - Hexosaminidase), Crigler-Najjar type II (du
  • Glycanosis CDG type 1 Hereditary emphysema (due to ⁇ l -Antitrypsin (PiZ variant), Congenital hyperthyroidism, Osteogenesis imperfecta (due to Type I, II, IV procollagen), Hereditary hypofibrinogenemia (due to Fibrinogen), ACT deficiency (due to ⁇ l-Antichymotrypsin), Diabetes insipidus (DI), Neurophyseal DI (due to Vasopvessin hormone/V2-receptor), Neprogenic DI (due to Aquaporin II), Charcot-Marie Tooth syndrome (due to Peripheral myelin protein 22), Perlizaeus- Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to ⁇ APP and presenilins), Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick
  • CFTR modulators may be beneficial for the treatment of secretory diarrheas, in which epithelial water transport is dramatically increased as a result of secretagogue activated chloride transport.
  • the mechanism involves elevation of cAMP and stimulation of CFTR.
  • Acute and chronic diarrheas represent a major medical problem in many areas of the world. Diarrhea is both a significant factor in malnutrition and the leading cause of death (5,000,000 deaths/year) in children less than five years old.
  • Diarrhea in barn animals and pets such as cows, pigs and horses, sheep, goats, cats and dogs, also known as scours, is a major cause of death in these animals. Diarrhea can result from any major transition, such as weaning or physical movement, as well as in response to a variety of bacterial or viral infections and generally occurs within the first few hours of the animal's life.
  • ETEC having the K99 pilus antigen.
  • Common viral causes of diarrhea include rotavirus and coronavirus.
  • Other infectious agents include Cryptosporidium, giardia lamblia, and salmonella, among others.
  • Symptoms of rotaviral infection include excretion of watery feces, dehydration and weakness. Coronavirus causes a more severe illness in the newborn animals, and has a higher mortality rate than rotaviral infection. Often, however, a young animal may be infected with more than one virus or with a combination of viral and bacterial microorganisms at one time. This dramatically increases the severity of the disease.
  • R 1 , R 2 , R 3 , R 4 , X, and m are described generally and in classes and subclasses below.
  • compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1,
  • the present invention relates to a method of modulating ABC transporter activity comprising the step of contacting said ABC transporter with a compounds of formula I:
  • Each R 1 is independently R', halo, NO 2 , or CN;
  • Each R 2 is independently -XR';
  • Each X is independently a bond or is an optionally substituted Ci .(, alkylidene chain wherein up to two methylene units of X are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -O-, -NR'CONR'-, -OCONR'-, -NR'NRS -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO 2 -, -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, Or -NR 5 SO 2 NR'-;
  • Each R' is independently selected from hydrogen or an optionally substituted group selected from a C 1 -S aliphatic group, a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic or tricyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R ' are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each R' group other than hydrogen is optionally substituted with 1-3 of -WR W .
  • Each m is independently 0-4;
  • Each R 3 is independently H or a C 1-8 aliphatic group optionally substituted with -X-R A and wherein up to two methylene units of the R 3 aliphatic group may be replaced by -CO-, -CH 2 S-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO 2 -, -NR 5 -, -SO 2 NR 5 -, -NR 5 SO 2 -, or -NR 5 SO 2 NR'-;
  • Each R A is independently R', halo, NO 2 , or CN; PCT ⁇ MiSRtKB ( ⁇ p ⁇ ' l ⁇ p ⁇ i ⁇ fclialkyl, (heterocycloaliphatic)alkyl, aralkyl, or heteroaralkyl wherein the alkyl portion of R 4 is optionally substituted with R 5 and wherein up to two methylene units of the alkyl portion of R 4 may be replaced by -CO-, -CS-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -O-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO 2 -, -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, or -NR 5
  • R 3 and R 4 together with the nitrogen to which they are attached may form a 5 to 7 membered heterocycloaliphatic optionally substituted with 1 to 3 R';
  • R B is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally fused with an aryl or heteroaryl, wherein R B attaches to the nitrogen atom of the core structure at the cycloaliphatic or heterocycloaliphatic ring, and R B is optionally substituted with 1-3 of -WR W ;
  • Each R 5 is independently aryl, heteroaryl, Ci -8 aralkyl, or Ci -8 heteroaralkyl wherein the alkyl portion of R 5 is optionally substituted with R w and wherein up to two methylene units of the alkyl portion of R 5 may be replaced by -CO-, -CS-, -CONR'-, -CONR 5 NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -0-, -NR'CONR'-, -OCONR 5 -, -NR 5 NR'-, -NR'NR'CO-, -NR 5 CO-, -S-, -SO-, -SO 2 - , -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, or -NR 5 SO 2 NR'-, and the aryl or heteroaryl portions of R 5 are optionally substituted with 1-3 of-WR w ;
  • Each W is independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR 5 -, -CONR 5 NR 5 -, -CO 2 -, -OCO-, -NR 5 CO 2 -, -0-, -NR'CONR 5 -, -OCONR 5 -, -NR'NR'-, -NR'NR'CO-, -NR 5 CO-, -S-, -SO-, -SO 2 -, -NR 5 -, -SO 2 NR 5 -, -NR 5 SO 2 -, or -NR 5 SO 2 NR'-; and
  • Each R w is independently R', halo, NO 2 , CN, CF3, -O(C 1-4 alkyl), -OCF 3 , or phenyl that is optionally substituted with 1-3 halo, haloalkyl, alkoxy, or aliphatic;
  • the compounds do not include, at the 5 position of the indole, the groups: -C(0)-(optionally substituted piperidinyl)-CH 2 -(optionally substituted phenyl), or -C(O)-(optionally substituted piperaziny I)-(C i. 4 alkyl)-(optionally substituted phenyl).
  • P C ⁇ ..'[ ' OMiSIJ la .. • ' ⁇ ' ⁇ i ⁇ i ⁇ llIBC-transporter” as used herein means an ABC-transporter protein or a fragment thereof comprising at least one binding domain, wherein said protein or fragment thereof is present in vivo or in vitro.
  • binding domain means a domain on the ABC-transporter that can bind to a modulator. See, e.g., Hwang, T. C. et al, J. Gen. Physiol. (1998): 111(3), 477-90.
  • CFTR cystic fibrosis transmembrane conductance regulator or a mutation thereof capable of regulator activity, including, but not limited to, ⁇ F508 CFTR and G551D CFTR (see, e.g., http://www.genet.sickkids.on.ca/cftr/, for CFTR mutations).
  • modulating means increasing or decreasing, e.g. activity, by a measurable amount.
  • Compounds that modulate ABC Transporter activity, such as CFTR activity, by increasing the activity of the ABC Transporter, e.g., a CFTR anion channel are called agonists.
  • Compounds that modulate ABC Transporter activity, such as CFTR activity, by decreasing the activity of the ABC Transporter, e.g., CFTR anion channel are called antagonists.
  • An agonist interacts with an ABC Transporter, such as CFTR anion channel, to increase the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • An antagonist interacts with an ABC Transporter, such as CFTR, and competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor to decrease the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • ABC Transporter such as CFTR
  • the phrase "treating or reducing the severity of an ABC Transporter mediated disease” refers both to treatments for diseases that are directly caused by ABC Transporter and/or CFTR activities and alleviation of symptoms of diseases not directly caused by ABC Transporter and/or CFTR anion channel activities.
  • diseases whose symptoms may be affected by ABC Transporter and/or CFTR activity include, but are not limited to, Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Con
  • compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
  • aliphatic encompasses the terms alkyl, alkenyl, and alkynyl.
  • alkylidene chain or “alkylidene” refers to a straight or branched carbon chain that may be fully saturated, e.g., alkyl, or have one or more units of unsaturation, e.g., alkenyl or alkynyl, and has two points of attachment to the rest of the molecule.
  • spirocycloalkylidene refers to a carbocyclic ring that may be fully saturated or have one or more units of unsaturation and has two points of attachment from the same ring carbon atom to the rest of the molecule.
  • an "alkyl” group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms.
  • An alkyl group can be straight or branched. Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, and 2-ethylhexyl.
  • An alkyl group can be optionally substituted with one or more substituents such as cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a ring together with the atom(s) to which they are bound), aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, acyl, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfmyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl,
  • substituents such as cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a
  • an "alkenyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl.
  • An alkenyl group can be optionally substituted with one or more substituents such as cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a ring together with the atom(s) to which they are bound), aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, acyl, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl.cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, hetero
  • an "alkynyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and has at least one triple bond.
  • An alkynyl group can be straight or branched. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl.
  • An alkynyl group can be optionally substituted with one or more substituents such as cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a ring together with the atom(s) to which they are bound), aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, acyl, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl.cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy,
  • an “amino” group refers to -NR X R Y wherein each of R x and R ⁇ is independently hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl, or heteroaralkyl each of which are defined herein and are optionally substituted.
  • R x has the same meaning as defined above.
  • an "aryl” group used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl” refers to phenyl, naphthyl, or a benzofused group having 2 to 3 rings.
  • a benzofused group includes phenyl fused with one or two C 4- 8 carbocyclic moieties, e.g., 1, 2, 3, 4-tetrahydronaphthyl, indanyl, or fluorenyl.
  • An aryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, , alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycl
  • an "aralkyl” group refers to an alkyl group (e.g., a Ci -4 alkyl group) that is substituted with an aryl group. Both “alkyl” and “aryl” are defined herein. An example of an aralkyl group is benzyl. An “heteroaralkyl” group refers to an alkyl group that is substituted with a heteroaryl. Both “alkyl” and “heteroaryl” are defined herein.
  • a "cyclcoaliphatic” group encompasses a “cycloalkyl” group and a “cycloalkenyl” group.
  • a "cycloalkyl” group refers to a saturated carbocyclic mono- or bicyclic (fused or bridged) ring of 3-10 (e.g., 5-10) carbon atoms.
  • Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, and bicyclo[3.3.2.]decyl, and adamantyl.
  • a "cycloalkenyl” group refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4- S! SbSi double bond.
  • Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, bicyclo[2.2.2]octenyl, and bicyclo[3.3.1]nonenyl.
  • a cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalky ⁇ alkylcarbonylamino, arylcarbonylamino, aralkylcarbon
  • a bicyclicaliphatic ring system encompasses bridged and fused cycloaliphatic ring systems which can be substituted with the substituents of a cycloaliphatic.
  • heterocycloaliphatic encompasses a heterocycloalkyl group and a heterocycloalkenyl group.
  • heterocycloalkyl refers to a 3- to 10-membered mono- or bicylic (fused or bridged) (e.g., 5- to 10-membered mono- or bicyclic) saturated ring structure, in which one or more of the ring atoms is a heteroatom, e.g., N, O, or S.
  • heterocycloalkyl group examples include piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuryl, dioxolanyl, oxazolidinyl, isooxazolidinyl, morpholinyl, octahydro-benzofuryl, octahydro- chromenyl, octahydro-thiochromenyl, octahydro-indolyl, octahydro-pyrindinyl, decahydro- quinolinyl, octahydro-benzo[ ⁇ ]thiopheneyl, 2-oxa-bicyclo[2.2.2]octyl, 1 -aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.0 3 ' 7 ]nonyl.
  • a monocyclic heterocycloalkyl group may be fused with a phenyl moiety such as tetrahydroisoquinoline.
  • a "heterocycloalkenyl” group refers to a mono- or bicylic (e.g., 5- to 10-membered mono- or bicyclic) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom, e.g., N, O, or S.
  • a heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl (such as a benzimidazolidinyl), (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or .f ⁇ r ⁇ ifflg ⁇ dibther with the atom(s) to which they are bound), cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbony
  • a bicyclicheteroaliphatic ring system encompasses bridged and fused cycloheteroaliphatic ring systems which can be substituted with the substituents of a heterocycloaliphatic.
  • a “heteroaryl” group refers to a monocyclic, bicyclic, or tricyclic ring structure having 4 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom, e.g., N, O, or S and wherein one ore more rings of the bicyclic or tricyclic ring structure is aromatic.
  • a heteroaryl group includes a benzofused ring system having 2 to 3 rings.
  • a benzofused group includes phenyl fused with one or two C 4-8 heterocyclic moieties, e.g., indolinyl and tertahydoquinolinyl.
  • heteroaryl examples include azetidinyl, pyridyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, tetrazolyl, benzofuryl, isoquinolinyl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, and benzo[l,3]dioxole.
  • a heteroaryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkytyalkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloal
  • heteroaryl group refers to an alky] group (e.g., a Ci- 4 alkyl group) that is substituted with a heteroaryl group. Both “alkyl” and “heteroaryl” have been defined above.
  • cyclic moiety includes cycloalkyl, heterocycloalkyl, FfijElSlkeif'l ⁇ ihEtfffl ⁇ fSSlil ⁇ K ⁇ Ilyl, or heteroaryl, each of which has been defined previously.
  • a “carbamoyl” group refers to a group having the structure
  • R x and R ⁇ have been defined above and R z can be alkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl.
  • a "carboxy” and a “sulfo" group refer to -COOH or
  • an "alkoxy” group refers to an alkyl-O- group where
  • alkyl has been defined previously.
  • a "sulfoxy" group refers to -O-SO-R X or -SO-O-R X , where R x has been defined above.
  • a "sulfonyl” group refers to -S(O) 2 -R X , wherein R x has been defined above.
  • sulfinyl refers to -S(O)-R X , wherein R x has been defined above.
  • sulfanyl group refers to -S-R x , wherein R x has been defined above.
  • halogen or halo group refers to fluorine, chlorine, bromine or iodine.
  • haloaliphatic refers to an aliphatic group substituted with 1-3 halogen.
  • haloalkyl includes the group -CF3.
  • a "sulfamoyl” group refers to the structure -S(O) 2 -NR X R Y or -NR X ⁇ S(O) 2 -R Z wherein R x , R ⁇ , and R z have been defined above.
  • sulfamide refers to the structure -NR X -S(O) 2 -
  • a "carbonylamino" group used alone or in connection with another group refers to an amido group such as -C(O)-NR X -, -NR X -C(O)-, and -C(O)-N(R X ) 2 .
  • an alkylcarbonylamino includes alkyl-C(O)-NR x - and alkyl-NR x -C(O)-.
  • a "urea” group refers to the structure -NR X -CO-NR Y R Z and a “thiourea” group refers to the structure -NR X -CS-NR Y R Z .
  • R x , R ⁇ , and R z have been [00167]
  • the phrase "optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.”
  • compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
  • the variables encompass specific groups, such as alkyl and aryl.
  • each of the specific groups for the variables described herein with respect to fo ⁇ nulae I, II, III, Ilia, and IV may be optionally substituted with one or more substituents described herein.
  • Each substituent of a specific group is further optionally substituted with one to three of halo, cyano, alkoxy, hydroxyl, nitro, haloalkyl, and alkyl.
  • an alkyl group may be substituted with alkylsulfanyl and the alkylsulfanyl may be optionally substituted with one to three of halo, cyano, alkoxy, hydroxyl, nitro, haloalkyl, and alkyl.
  • an alkyl may be substituted with a (cycloalkyl)carbonylamino.
  • the cycloalkyl portion of the (cycloalkyl)carbonylamino is optionally substituted with one to three of halo, cyano, alkoxy, hydroxyl, nitro, haloalkyl, and alkyl.
  • an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • a ring substituent such as a heterocycloalkyl, may be bound to another ring, such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g., both rings share one common atom.
  • substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • stable or chemically feasible refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • an effective amount is defined as the amount required to ⁇ ⁇ eii!9i ' : ⁇ liH €&ated patient, and is typically determined based on age, surface area, weight, and condition of the patient.
  • the interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966).
  • Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, New York, 537 (1970)/
  • patient refers to a mammal, including a human.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) confo ⁇ national isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a i3 C- or 14 C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • Each AA and AB is independently aryl, heteroaryl, or heterocycloaliphatic each optionally substituted with 1-3 of -WR W ;
  • Each Y 1 and Y 2 is independently a bond or is an optionally substituted Cj -6 alkylidene chain wherein up to two methylene units of the Ci -6 alkylidene chain are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR 5 CO-, -S-, -SO-, -SO 2 - , -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, or -NR 5 SO 2 NR'-;
  • Each W is independently a bond or is an optionally substituted C 1 - 6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR 5 -, -CONR'NR 5 -, -CO 2 -, -OCO-, -NR 5 CO 2 -, -O-, -NR'CONR 5 -, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO 2 -, -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, or -NR 5 SO 2 NR 5 -;
  • Each R w is independently R 5 , halo, NO 2 , CN, CF 3 , -O(C M alkyl) or -OCF 3 ;
  • Each E is a independently a bond or is an optionally substituted Ci -6 alkylidene chain wherein up to two methylene units of the Ci -6 alkylidene chain are optionally and independently replaced by -C(O)-, -CS-, -COCO-, CONR'-, -CONR'NR 5 -, -CO 2 -, -OCO-, -NR 5 CO 2 , -0-, -OCONR'-, -NR 5 NR'-, -NR'NR'CO-, -NR 5 CO-, -S-, -SO-, SO 2 -, -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, or -NR 5 SO 2 NR'-;
  • Each R 10 is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally substituted with 1-3 halo, haloalkyl, alkoxy, aliphatic, aryl, or heteroaryl, in which the aryl and heteroaryl are each optionally substituted with 1-3 of halo, alkoxy, haloalkyl, aliphatic; and
  • Each p is 0-3.
  • the compounds of formula III include the structure Ilia:
  • each R 1 , R 2 , R 3 , X, R', and m are as defined above;
  • Ring Z z is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally substituted with 1-3 halo, haloalkyl, alkoxy, aliphatic, aryl, or heteroaryl, in which the aryl and heteroaryl are each optionally substituted with 1-3 of halo, alkoxy, haloalkyl, or aliphatic;
  • Each R E is independently halo, haloalkyl, alkoxy, or aliphatic;
  • Each d is independently 0 to 3.
  • Each R ⁇ is aryl or heteroaryl, each of which is optionally substituted with 1-3 halo, aliphatic, aryl, or heteroaryl;
  • Each q is 0-3.
  • R is hydrogen.
  • R is C1-C6 aliphatic.
  • R includes C1-C6 alkyl e.g., methyl, ethyl, propyl, or butyl.
  • R' is hydrogen
  • R' is a C1-C8 aliphatic group, optionally substituted with up to 3 substituents selected from halo, CN, CF 3 , CHF 2 , OCF 3 , or OCHF 2 , wherein up to two methylene units of said C1-C8 aliphatic is optionally replaced with -CO-, -CONH(C1 ⁇ C4 alkyl)-, -CO 2 -, -OCO-, -N(Cl -C4 alkyl)CO 2 -, -O-, -N(C1-C4 alkyl)CON(Cl-C4 alkyl)-, -OCON(C1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO 2 N(C1-C4 alkyl)-, N(C1-C4 alkyl)
  • R' is a C 1-C4 alkyl or a C2-C4 alkenyl, optionally substituted with up to 3 substituents selected from halo, CN, CF 3 , CHF 2 , OCF 3 , or OCHF 2 , wherein up to two methylene units of said C1-C4 alkyl or a C2-C4 alkenyl is optionally replaced with -CO-, -CONH(C1-C4 alkyl)-, -CO 2 -, -OCO-, -N(C1-C4 alkyl)CO 2 -, -O-, -N(C1-C4 alkyl)CON(Cl-C4 alkyl)-, -OCON(C1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO 2 N(C1-C4
  • R' is a C 1-C4 alkyl or a C2-C4 alkenyl, optionally SfsySst ⁇ FutelM halo, CN, CF 3 , CHF 2 , OCF 3 , Or OCHF 2 .
  • R' is a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , or C1-C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C 1-C4 alkyl)-, -CO 2 -, -OCO-, -N(C1-C4 alkyl)CO 2 -, -0-, -N(C1-C4 alkyl)CON(Cl-C4 alkyl)-, -OCON(C1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C
  • R' is a 3-8 membered cycloalkyl ring independently selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , or C1-C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C 1-C4 alkyl)-, -CO 2 -, -OCO-, -N(C1-C4 alky I)CO 2 -, -0-, -N(C1-C4 alkyl)C0N(Cl-C4 alkyl)-, -OCON(C 1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO 2 N
  • R' is a 3-8 membered saturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , or C1-C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C 1-C4 alkyl)-, -CO 2 -, -OCO-, -N(C1-C4 alkyl)CO 2 -, -0-, -N(Cl- C4 alkyl)C0N(Cl-C4 alkyl)-, -OCON(C 1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -S-, -N
  • R' is a 3-8 membered saturated monocyclic ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , or Cl- C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C1-C4 alkyl)-, -CO 2 -, -OCO-, -N(C1-C4 alkyl)CO 2 -, -0-, -N(C1-C4 alkyl)C0N(Cl-C4 alkyl)-, -OCON(C 1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(Cl -C4 alkyl)-, -SO
  • R' is an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , or C1-C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C 1-C4 alkyl)-, -CO 2 -, -OCO-, -N(C1-C4 alky I)CO 2 -, -0-, -N(C1-C4 alkyl)CON(Cl-C4 alkyl)-, -OCON(C 1-C4 alkyl)-, -N(
  • two occurrences of R' are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , or C1-C6 alkyl, wherein up to two methylene .units of said C1-C6 alkyl is optionally replaced with -CO-, - CONH(C1-C4 alkyl)-, -CO 2 -, -OCO-, -N(C1-C4 alkyl)CO 2 -, -O-, -N(C1-C4 alkyl)C0N(Cl-C4 alkyl)-, -0C0N(
  • R 3 is independently H or a Q.g aliphatic group optionally substituted with -X-R ⁇ . In several examples, R 3 is H.
  • R 4 is (cycloaliphatic)alkyl
  • R 4 is an aralkyl or a heteroaralkyl each optionally substituted with WR W .
  • each R 4 is Ci -8 aralkyl or Cj -8 heteroaralkyl wherein the alkyl portion of R 4 is optionally substituted with R 5 and wherein up to two methylene units of the alkyl portion of R 4 may be replaced by -CO-, -CS-, -CONR'-, -CONR'NR'-, -CO 2 -, -OCO-, -NR 5 CO 2 -, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO 2 -, -NR'-, -SO 2 NR'-, -NR 5 SO 2 -, Or -NR 5 SO 2 NR'-, and the aryl or heteroaryl portions of R 4 are optionally substituted with 1-3 of -WR W .
  • R is Cj -8 aralkyl or C ]-8 heteroaralky in which the aryl or heteroaryl portions of are optionally substituted with 1-3 of -WR W .
  • R 4 is a -(Ci -4 alkyl)- aryl in which the aryl is optionally substituted with 1-3 of -WR W .
  • R 4 is a -(Ci -4 alkyl)-aryl in which the aryl is substituted with 1-2 substituents independently selected from alkoxy, halo, liSj ⁇ a ⁇ dilkylcarbonyl .
  • R 4 is a -(C ⁇ alkyl)-heteroaryl in which the heteroaryl is optionally substituted with 1-3 of -WR .
  • R is a -(Ci 4 alkyl)-heteroaryl in which the heteroaryl is substituted with 1-2 substituents independently selected from alkoxy, halo, alkylcarbonylamino, aliphatic, alkylarylalkyl, and alkylcarbonyl.
  • R 4 is Ci -8 aralkyl or Ci -8 heteroaralky in which the aryl or heteroaryl portions are optionally substituted with 1-3 of -WR W and wherein one or two non-adjacent methylene units in the Q ⁇ alkyl portion are optionally and independently replaced by -O-, -NR'-, -S-, -SO 2 -, -COO-, or -CO-.
  • R 4 is Ci -8 aralkyl or Ci -8 heteroaralky in which the aryl or heteroaryl portions are optionally substituted with 1-3 of -WR W and wherein one or two non-adjacent methylene units in the Ci -4 alkyl portion are optionally and independently replaced by O, NR', or S.
  • R 4 is cycloaliphatic or a heterocycloaliphatic, each of which is optionally substituted with 1-3 -WR W .
  • R 4 is a monocyclic cycloaliphatic or a monocyclic heterocyclicaliphatic.
  • R 4 is cyclohexyl, cyclopentyl, cyclobutyl, or cyclopropyl, each of which is optionally substituted with 1-3 of -WR W .
  • R 4 is cycloaliphatic and R 4 is substituted with an optionally substituted aryl. More specific examples of R 4 include cyclohexyl, cyclopentyl, or cyclopropyl that is monosubstituted with an optionally substituted phenyl.
  • R 4 is piperidinyl, or tetrahydropyrrolyl, each of which is optionally substituted with 1-3 of -WR W .
  • R 4 is a bicyclicaliphatic or a bicyclicheteroaliphatic, each of the bicyclicaliphatic or the bicyclicheteroaliphatic is optionally substituted with 1-3 of -WR W .
  • R 4 is a bicyclicaliphatic optionally substituted with 1-3 of -WR W .
  • R 4 is noboraanyl optionally substituted with 1-3 of -WR W .
  • R 4 is tropane optionally substituted with 1-3 of -WR W .
  • R 5 is an optionally substituted Ci -4 aliphatic group.
  • R B is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally fused with an aryl or heteroaryl wherein R B attaches to the amino nitrogen atom of core structure at any chemically viable position on the cycloaliphatic or heterocycloaliphatic ring, and R B is optionally substituted with 1-3 of -WR W .
  • R B is where R B is optionally substituted with 1 -3 -WR W at any chemically viable position, wherein -WR W is defined above.
  • R B is
  • R B is indolizinyl, indolyl, indolinyl, benzo[Z>]furyl, benzo[ ⁇ ]thiophenyl, hydroindazolyl, benzimidazolyl, benzthiazolyl, purinyl, or indenyl; each of which is optionally substituted with 1-3 alkoxy, aliphatic, halo, or alkylcarbonyl.
  • W is a bond or is an optionally substituted Cue alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by -O-, -NR'-, -S-, -SO 2 -, -COO-, or -CO-.
  • R w is R' or halo.
  • each occurrence of WR W is independently -Ci-3alkyl, -O(C 1-3 alkyl), -CF 3 , -OCF 3 , -SCF 3 , -F, -Cl, -Br, or -COOR', -COR', -O(CH 2 ) 2 N(R')(R'), -O(CH 2 )N(R')(R'), -CON(R')(R') > -(CH 2 ) 2 OR ⁇ -(CH 2 )OR', optionally substituted monocyclic or bicyclic aromatic ring, optionally substituted arylsulfonyl, optionally substituted 5-membered heteroaryl ring, -N(R')(R'), -(CH 2 ) 2 N(R')(R'), or -(CH 2 )N(R 1 XR').
  • W is a bond and R 1 is halo or R'.
  • m is 1 or 2.
  • m is 0. Or, m is 1. Or, m is 2. In some embodiments, m is 3. In yet other embodiments, m is 4.
  • R 2 is hydrogen. Or, R 2 is an optionally substituted
  • Ci -8 aliphatic group In some embodiments, R 2 is optionally substituted Q-4 aliphatic.
  • R 1 is X-R A , wherein X is -SO 2 NR'-, and R A is R'.
  • X is a bond or is an optionally substituted Ci -6 alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by -O-, -NR-, -S-, -SO 2 -, -COO-, or -CO-.
  • R A is R' or halo.
  • each occurrence of XR A is independently -Ci -3 alkyl, -O(Ci -3 alkyl), -CF 3 , -OCF 3 , -SCF 3 , -F, -Cl, -Br, or -COOR', -COR', -O(CH 2 ) 2 N(R)(R'), -0(CH 2 )N(R)(R'), -CON(R)(R'), -(CH 2 J 2 OR', -(CH 2 )OR', optionally substituted phenyl, -N(R)(R'), -(CH 2 ) 2 N(R)(R'), or -(CH 2 )N(R)(R').
  • R 3 is hydrogen. In certain other embodiment, R 3 is
  • R w is selected from hydrogen, aliphatic, alkylcarbonylamino, or alkoxy.
  • each occurrence of WR W is independently
  • -WR W is selected from aliphatic, alkoxy, or alkylcarbonylamin
  • R 10 in formula III is cycloaliphatic. Examples of
  • R 10 include cyclohexyl, cyclopropyl, cyclopentyl, or cyclobutyl, each of which is optionally substituted with 1-3 aliphatic, aryl, or heteroaryl. If R 10 is substituted with aliphatic, halo, aryl, or heteroaryl, said aliphatic, halo, aryl, or heteroaryl can be optionally substituted with 1-3 alkoxy, halo, or aliphatic.
  • R 10 is heterocycloaliphatic. Examples of
  • R 10 include tetrahydrofuryl, piperidinyl, or pyrrolidinyl, each of which is optionally substituted with 1-3 aliphatic, halo, aryl, or heteroaryl. IfR 10 is substituted with aliphatic, halo, aryl, or heteroaryl, said aliphatic, halo, aryl, or heteroaryl can be optionally substituted with 1-3 alkoxy, halo, or aliphatic.
  • R 10 in formula III, is one selected from:
  • R 11 is an optionally substituted aryl or heteroaryl.
  • R 11 is optionally substituted with 1-3 substituents independently selected from halo, aliphatic, aryl, heteroaryl, and alkoxy. IfR 11 is substituted with an aliphatic, aryl, heteroaryl, or alkoxy, said aliphatic, aryl, heteroaryl, or alkoxy can be optionally substituted with 1-3 alkoxy, aliphatic, or halo.
  • R 11 is one selected from:
  • R 3 and R 4 together form a 5 to 7 membered heterocycloaliphatic optionally substituted with 1-3 of -WR w .
  • R and R 4 together form an optionally substituted piperidine or an optionally substituted piperazine.
  • Representative compounds of the invention include:
  • the present invention provides compounds that are useful as modulators of ABC transporters and thus are useful in the treatment of disease, disorders or conditions such as Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Heredit
  • compositions comprising any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle.
  • these compositions optionally further comprise one or more additional therapeutic agents.
  • a pharmaceutically acceptable derivative or a prodrug includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative I ⁇ EcffupdyalmlHSMratiitficiipL ⁇ nt in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a “pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • suitable inorganic and organic acids and bases examples include those derived from suitable inorganic and organic acids and bases.
  • pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (Ci. 4 alkyl) 4 salts.
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington The Science and Practice of Pharmacy, 21st edition, 2005, ed. D.B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, e
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc
  • the present invention provides a method of treating Mon
  • the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of ABC transporter activity, the method comprising administering a composition comprising a compound of formula (I) to a subject, preferably a mammal, in need thereof.
  • the present invention provides a method of treating Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism,
  • the present invention provides a method of treating cystic fibrosis comprising the step of administering to said mammal a composition comprising the step of administering to said mammal an effective amount of a composition comprising a compound of fo ⁇ nula (I), or a preferred embodiment thereof as set forth above.
  • an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary i ⁇ id ⁇ 4SPl ⁇ frdci ⁇ Sgi:iB?iObncies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism
  • the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis
  • L. il required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors known in the medical arts.
  • patient means an animal, for example, a mammal, and more specifically a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents,
  • the oral compositions can also include adjuvants such as wetting agents, 'emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, 'emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • ff%arati ⁇ ns for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • a nontoxic parenterally acceptable diluent or solvent for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • a compound of the present invention In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium Pi ⁇ pSateiyiRillEpfitfeBeStBffirs such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transde ⁇ nal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin.
  • the rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the compounds of the invention are useful as modulators of ABC transporters.
  • the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of ABC transporters is implicated in the disease, condition, or disorder.
  • hyperactivity or inactivity of an ABC transporter is implicated in a particular disease, condition, or disorder
  • the disease, condition, or disorder may also be referred to as a "ABC transporter-mediated disease, condition or disorder”.
  • the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of an ABC transporter is implicated in the disease state.
  • ABC transporter may be assayed according to methods described generally in the art and in the Examples herein.
  • the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects).
  • additional therapeutic agents that are normally administered to treat or prevent a lpaiicfikr Ifsiyiii ⁇ -.coiiSyiisiiMllnown as "appropriate for the disease, or condition, being treated”.
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the present invention in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Another aspect of the invention relates to modulating ABC transporter activity in a biological sample or a patient (e.g., in vitro or in vivo), which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Modulation of ABC transporter activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of ABC transporters in biological and pathological Sntfm ⁇ nltt Eml ' MS c6 ⁇
  • a method of modulating activity of an anion channel in vitro or in vivo comprising the step of contacting said channel with a compound of formula (I).
  • the anion channel is a chloride channel or a bicarbonate channel. In other preferred embodiments, the anion channel is a chloride channel.
  • the present invention provides a method of increasing the number of functional ABC transporters in a membrane of a cell, comprising the step of contacting said cell with a compound of formula (I).
  • the term "functional ABC transporter” as used herein means an ABC transporter that is capable of transport activity.
  • said functional ABC transporter is CFTR.
  • the activity of the ABC transporter is measured by measuring the transmembrane voltage potential.
  • Means for measuring the voltage potential across a membrane in the biological sample may employ any of the known methods in the art, such as optical membrane potential assay or other electrophysiological methods.
  • the optical membrane potential assay utilizes voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR Voltage/Ion Probe Reader
  • These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC 2 (3), and a fluorescent phospholipid, GC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor.
  • FRET fluorescence resonant energy transfer
  • V m fluorescent phospholipid
  • the changes in fluorescence emission can be monitored using VIPRTM II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates.
  • the present invention provides a kit for use in measuring the activity of a ABC transporter or a fragment thereof in a biological sample in vitro or in vivo RKpliS'inl- ⁇ iyESdliip ⁇ s ⁇ lffiSbS'fiBsing a compound of formula (I) or any of the above embodiments; and (ii) instructions for a) contacting the composition with the biological sample and b) measuring activity of said ABC transporter or a fragment thereof.
  • the kit further comprises instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said ABC transporter or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the ABC transporter in the presence of the additional compound with the density of the ABC transporter in the presence of a composition of formula (I).
  • the kit is used to measure the density of CFTR.
  • N-Benzhydryl-2-(lH-indol-3-yl)-2-oxo-acetamide was synthesized following scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and C,C-diphenyl- methylamine. Yield (52 %). HPLC ret.
  • N,N-Dibenzyl-2-(lH-indol-3-yl)-2-oxo-acetamide was synthesized following scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and dibenzylamine. Yield (58 %). HPLC ret.
  • N-Benzhydryl-2-(l-methyl-lH-indol-3-yl)-2-oxo-acetamide was synthesized following scheme II above starting from (1 -methyl- lH-indol-3-yl)-oxo-acetic acid and CC-diphenyl-methylamine. Yield (11 %). HPLC ret.
  • N-Benzyl-2-(lH-indol-3-yl)-N-methyl-2-oxo-acetamide was synthesized following scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and benzyl-methyl- amine. Yield (54 %). HPLC ret.
  • N,N-Dibenzyl-2-(l-methyl-lH-indol-3-yl)-2-oxo-acetamide was synthesized following scheme II above starting from (1 -methyl- lH-indol-3-yl)-oxo-acetic acid and dibenzylamine. Yield (70 %). HPLC ret.
  • N-(2,2-Diphenylethyl)-2-(lH-indol-3-yl)-2-oxo-acetamide was synthesized following the scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and 2,2-diphenyl-ethylamine. Yield (48 %). HPLC ret.
  • the optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) “Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR Voltage/Ion Probe Reader
  • Bath Solution #1 (in mM) NaCl 160, KCl 4.5, CaCl 2 2, MgCl 2 1, HEPES 10, pH 7.4 with NaOH.
  • Chloride-free bath solution Chloride salts in Bath Solution #1 are substituted with gluconate salts.
  • CC2-DMPE Prepared as a 10 mM stock solution in DMSO and stored at -2O 0 C.
  • DiSBAC 2 (3) Prepared as a 10 mM stock in DMSO and stored at -20 0 C.
  • NIH3T3 mouse fibroblasts stably expressing ⁇ F508-CFTR are used for optical measurements of membrane potential.
  • the cells are maintained at 37 0 C in 5% CO 2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, D-ME, 1 X pen/strep, and 25 mM HEPES in 175 cm 2 culture flasks.
  • the cells were seeded at 30,000/well in 384-well matrigel-coated plates and cultured for 2 hrs at 37 0 C before culturing at 27 0 C for 24 hrs.
  • the FRT epithelia demonstrated resistances of 4 K ⁇ / cm 2 or more.
  • the solutions were maintained at 27 0 C and bubbled with air.
  • the electrode offset potential and fluid resistance were corrected using a cell-free insert.
  • the current reflects the flow of Cl " through ⁇ F508-CFTR expressed in the apical membrane.
  • the Isc was digitally acquired using an MPlOOA-CE interface and AcqKnowledge software (v3.2.6; BIOPAC Systems, Santa Barbara, CA).
  • Typical protocol utilized a basolateral to apical membrane Cl " concentration gradient. To set up this gradient, normal ringer was used on the basolateral membrane, whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl " concentration gradient across the epithelium. All experiments were performed with intact monolayers. To fully activate ⁇ F508-CFTR, forskolin (10 ⁇ M) and the PDE inhibitor, IBMX (100 ⁇ M), were applied followed by the addition of the CFTR potentiator, genistein (50 ⁇ M).
  • Typical protocol utilized a basolateral to apical membrane Cl " concentration gradient.
  • normal ringers was used on the basolateral membrane and was permeabilized with nystatin (360 ⁇ g/ml), whereas apical NaCI was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl " concentration gradient across the epithelium. All experiments were performed 30 min after nystatin permeabilization. Forskolin (10 ⁇ M) and all test compounds were added to both sides of the cell culture inserts. The efficacy of the putative ⁇ F508-CFTR potentiators was compared to that of the known potentiator, genistein.
  • Basolateral solution in mM: NaCl (135), CaCl 2 (1.2), MgCl 2 (1.2), K 2 HPO 4 (2.4),
  • FRT Fisher rat epithelial cells expressing ⁇ F508-CFTR
  • FRT ⁇ F508 - CFTR Fisher rat epithelial cells expressing ⁇ F508-CFTR
  • the cells were cultured on Costar Snapwell cell culture inserts and cultured for five days at 37 0 C and 5% CO 2 in Coon's modified Ham's F-12 medium supplemented with 5% fetal calf serum, 100 U/ml penicillin, and 100 ⁇ g/ml streptomycin.
  • the cells Prior to use for characterizing the potentiator activity of compounds, the cells were incubated at 27 0 C for 16 - 48 hrs to correct for the ⁇ F508-CFTR. To determine the activity of corrections compounds, the cells were incubated at 27 0 C or 37 0 C with and without the compounds for 24 hours.
  • the cells were incubated with 10 ⁇ M of the test compound for 24 hours at 37 0 C and the current density was compared to the 27 0 C and 37 0 C controls (% activity). Prior to recording, the cells were washed 3X with extracellular recording medium to remove any remaining test compound. Preincubation with 10 ⁇ M of correction compounds significantly increased the cAMP- and genistein-dependent current compared to the 37 0 C controls.
  • ⁇ F508-CFTR Cl current (I ⁇ F SOS ) in NIH3T3 cells stably expressing ⁇ F508-CFTR was also investigated using perforated-patch-recording techniques.
  • the potentiators identified from the optical assays evoked a dose-dependent increase in I ⁇ F SOS with similar potency and efficacy observed in the optical assays.
  • the reversal potential before and during potentiator application was around -30 mV, which is the calculated Eci (-28 mV),
  • NIH3T3 mouse fibroblasts stably expressing ⁇ F508-CFTR are used for whole-cell recordings.
  • the cells are maintained at 37 0 C in 5% CO 2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, ⁇ -ME, 1 X pen/strep, and 25 mM HEPES in 175 cm 2 culture flasks.
  • 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 0 C before use to test the activity of potentiators; and incubated with or without the correction compound at 37 0 C for measuring the activity of correctors.
  • the ⁇ F508-CFTR was activated after excision, by adding 1 mM Mg-ATP, and 75 nM of the cAMP-dependent protein kinase, catalytic subunit (PKA; Promega Corp. Madison, WI). After channel activity stabilized, the patch was perfused using a gravity- driven microperfusion system. The inflow was placed adjacent to the patch, resulting in complete solution exchange within 1 - 2 sec. To maintain ⁇ F508-CFTR activity during the rapid perfusion, the nonspecific phosphatase inhibitor F " (10 mM NaF) was added to the bath solution. Under these recording conditions, channel activity remained constant throughout the duration of the patch recording (up to 60 min). Currents produced by positive charge moving from the intra- to extracellular solutions (anions moving in the opposite direction) are shown as positive currents. The pipette potential (V p ) was maintained at 80 mV.
  • V p The pipette potential
  • Extracellular solution in mM: NMDG (150), aspartic acid (150), CaCl 2 (5), MgCl 2 (2), and HEPES (10) (pH adjusted to 7.35 with Tris base).
  • Intracellular solution in mM: NMDG-Cl (150), MgCl 2 (2), EGTA (5), TES (10), and Tris base (14) (pH adjusted to 7.35 with HCl).
  • NIH3T3 mouse fibroblasts stably expressing ⁇ F508-CFTR are used for excised-membrane patch-clamp recordings.
  • the cells are maintained at 37 0 C in 5% CO 2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, ⁇ -ME, 1 X pen/strep, and 25 mM HEPES in 175 cm 2 culture flasks.
  • 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 0 C before use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

The present invention relates to modulators of ATP-B inding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR'), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Description

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
CROSS-REFERENCE TO RELATED APPLICATIONS
[00100] The present application claims the benefit under 35 U.S.C. § 119 of
United States Provisional Application No. 60/724,736, filed October 6, 2005, the entire contents of the above application being incorporated herein by reference.
TECHNICAL FIELD OF THE INVENTION
[00101] The present invention relates to modulators of ATP-Binding Cassette
("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
BACKGROUND OF THE INVENTION
[00102] ABC transporters are a family of membrane transporter proteins that regulate the transport of a wide variety of pharmacological agents, potentially toxic drugs, and xenobiotics, as well as anions. ABC transporters are homologous membrane proteins that bind and use cellular adenosine triphosphate (ATP) for their specific activities. Some of these transporters were discovered as multidrug resistance proteins (like the MDRl-P glycoprotein, or the multidrug resistance protein, MRPl), defending malignant cancer cells against chemotherapeutic agents. To date, 48 ABC Transporters have been identified and grouped into 7 families based on their sequence identity and function.
[00103] ABC transporters regulate a variety of important physiological roles within the body and provide defense against harmful environmental compounds. Because of this, they represent important potential drug targets for the treatment of diseases associated with defects in the transporter, prevention of drug transport out of the target cell, and intervention in other diseases in which modulation of ABC transporter activity may be beneficial.
[00104] One member of the ABC transporter family commonly associated with disease is the cAMP/ATP-mediated anion channel, CFTR. CFTR is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue. CFTR is composed of
Figure imgf000003_0001
protein made up of a tandem repeate of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
[00105] The gene encoding CFTR has been identified and sequenced (See
Gregory, R. J. et al. (1990) Nature 347:382-386; Rich, D. P. et al. (1990) Nature 347:358-362), (Riordan, J. R. et al. (1989) Science 245:1066-1073). A defect in this gene causes mutations in CFTR resulting in Cystic Fibrosis ("CF"), the most common fatal genetic disease in humans. Cystic Fibrosis affects approximately one in every 2,500 infants in the United States. Within the general United States population, up to 10 million people carry a single copy of the defective gene without apparent ill effects. In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung disease.
[00106] In patients with cystic fibrosis, mutations in CFTR endogenously expressed in respiratory epithelia leads to reduced apical anion secretion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in CF patients. In addition to respiratory disease, CF patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, results in death. In addition, the majority of males with cystic fibrosis are infertile and fertility is decreased among females with cystic fibrosis. In contrast to the severe effects of two copies of the CF associated gene, individuals with a single copy of the CF associated gene exhibit increased resistance to cholera and to dehydration resulting from diarrhea - perhaps explaining the relatively high frequency of the CF gene within the population.
[00107] Sequence analysis of the CFTR gene of CF chromosomes has revealed a variety of disease causing mutations (Cutting, G. R. et al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell 61:863:870; and Kerem, B-S. et al. (1989) Science 245: 1073-1080; Kerem, B- S et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, > 1000 disease causing mutations in the CF gene have been identified (http://www.genet.sickkids.on.ca/cftr/). The most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as ΔF508-CFTR. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease .
[00108] The deletion of residue 508 in ΔF508-CFTR prevents the nascent protein from folding correctly. This results in the inability of the mutant protein to exit the ER, paSBT fa,f%l]ti|Ii |ksή3iϋfeϊiϋa@. As a result, the number of channels present in the membrane is far less than observed in cells expressing wild-type CFTR. In addition to impaired trafficking, the mutation results in defective channel gating. Together, the reduced number of channels in the membrane and the defective gating lead to reduced anion transport across epithelia leading to defective ion and fluid transport. (Quinton, P. M. (1990), FASEB J. 4: 2709- 2727). Studies have shown, however, that the reduced numbers of ΔF508-CFTR in the membrane are functional, albeit less than wild-type CFTR. (Dalemans et al. (1991), Nature Lond. 354: 526-528; Denning et al., supra; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to ΔF508-CFTR, other disease causing mutations in CFTR that result in defective trafficking, synthesis, and/or channel gating could be up- or down-regulated to alter anion secretion and modify disease progression and/or severity.
[00109] Although CFTR transports a variety of molecules in addition to anions, it is clear that this role (the transport of anions) represents one element in an important mechanism of transporting ions and water across the epithelium. The other elements include the epithelial Na+ channel, ENaC, Na+/2C17K+ co-transporter, Na+-K+-ATPaSe pump and the basolateral membrane K+ channels, that are responsible for the uptake of chloride into the cell.
[00110] These elements work together to achieve directional transport across the epithelium via their selective expression and localization within the cell. Chloride absorption takes place by the coordinated activity of ENaC and CFTR present on the apical membrane and the Na+-K+-ATPaSe pump and Cl- channels expressed on the basolateral surface of the cell. Secondary active transport of chloride from the luminal side leads to the accumulation of intracellular chloride, which can then passively leave the cell via Cl" channels, resulting in a vectorial transport. Arrangement of Na+/2C17K+ co-transporter, Na+-K+-ATPaSe pump and the basolateral membrane K+ channels on the basolateral surface and CFTR on the luminal side coordinate the secretion of chloride via CFTR on the luminal side. Because water is probably never actively transported itself, its flow across epithelia depends on tiny transepithelial osmotic gradients generated by the bulk flow of sodium and chloride.
[00111] In addition to Cystic Fibrosis, modulation of CFTR activity may be beneficial for other diseases not directly caused by mutations in CFTR, such as secretory diseases and other protein folding diseases mediated by CFTR. These include, but are not limited to, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.
[00112] COPD is characterized by airflow limitation that is progressive and not fully reversible. The airflow limitation is due to mucus hypersecretion, emphysema, and rbBήIhi6lWδI3bivafbB. SϊrHMlor wild-type CFTR offer a potential treatment of mucus hypersecretion and impaired mucociliary clearance that is common in COPD. Specifically, increasing anion secretion across CFTR may facilitate fluid transport into the airway surface liquid to hydrate the mucus and optimized periciliary fluid viscosity. This would lead to enhanced mucociliary clearance and a reduction in the symptoms associated with COPD. Dry eye disease is characterized by a decrease in tear aqueous production and abnormal tear film lipid, protein and mucin profiles. There are many causes of dry eye, some of which include age, Lasik eye surgery, arthritis, medications, chemical/thermal burns, allergies, and diseases, such as Cystic Fibrosis and Sjδgrens's syndrome. Increasing anion secretion via CFTR would enhance fluid transport from the corneal endothelial cells and secretory glands surrounding the eye to increase corneal hydration. This would help to alleviate the symptoms associated with dry eye disease. Sjδgrens's syndrome is an autoimmune disease in which the immune system attacks moisture-producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut. Symptoms, include, dry eye, mouth, and vagina, as well as lung disease. The disease is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymypositis/dermatomyositis. Defective protein trafficking is believed to cause the disease, for which treatment options are limited. Modulators of CFTR activity may hydrate the various organs afflicted by the disease and help to elevate the associated symptoms.
[00113] As discussed above, it is believed that the deletion of residue 508 in
ΔF508-CFTR prevents the nascent protein from folding correctly, resulting in the inability of this mutant protein to exit the ER, and traffic to the plasma membrane. As a result, insufficient amounts of the mature protein are present at the plasma membrane and chloride transport within epithelial tissues is significantly reduced. In fact, this cellular phenomenon of defective ER processing of ABC transporters by the ER machinery has been shown to be the underlying basis not only for CF disease, but for a wide range of other isolated and inherited diseases. The two ways that the ER machinery can malfunction is either by loss of coupling to ER export of the proteins leading to degradation, or by the ER accumulation of these defective/misfolded proteins [Aridor M, et al, Nature Med., 5(7), pp 745- 751 (1999); Shastry, B.S., et al, Neurochem. International, 43, pp 1-7 (2003); Rutishauser, J., et al, Swiss Med WkIy, 132, pp 211-222 (2002); Morello, JP et al, TIPS, 21, pp. 466- 469 (2000); Bross P., et al, Human Mut, 14, pp. 186-198 (1999)]. The diseases associated with the first class of ER malfunction are Cystic fibrosis (due to misfolded ΔF508-CFTR as discussed above), Hereditary emphysema (due to al- antitrypsin; non Piz variants), Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing PclSfi'(Iencyk!,'iiβHtis"f aiillaiϊipplilcholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses (due to Lysosomal processing enzymes), Sandhof/Tay-Sachs (due to β- Hexosaminidase), Crigler-Najjar type II (due to UDP-glucuronyl-sialyc-transferase), Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus (due to Insulin receptor), Laron dwarfism (due to Growth hormone receptor), Myleoperoxidase deficiency, Primary hypoparathyroidism (due to Preproparathyroid hormone), Melanoma (due to Tyrosinase). The diseases associated with the latter class of ER malfunction are Glycanosis CDG type 1, Hereditary emphysema (due to αl -Antitrypsin (PiZ variant), Congenital hyperthyroidism, Osteogenesis imperfecta (due to Type I, II, IV procollagen), Hereditary hypofibrinogenemia (due to Fibrinogen), ACT deficiency (due to αl-Antichymotrypsin), Diabetes insipidus (DI), Neurophyseal DI (due to Vasopvessin hormone/V2-receptor), Neprogenic DI (due to Aquaporin II), Charcot-Marie Tooth syndrome (due to Peripheral myelin protein 22), Perlizaeus- Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease ( due to βAPP and presenilins), Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease (due to Prion protein processing defect), Fabry disease (due to lysosomal α-galactosidase A) and Straussler-Scheinker syndrome (due to Prp processing defect).
[00114] In addition to up-regulation of CFTR activity, reducing anion secretion by
CFTR modulators may be beneficial for the treatment of secretory diarrheas, in which epithelial water transport is dramatically increased as a result of secretagogue activated chloride transport. The mechanism involves elevation of cAMP and stimulation of CFTR.
[00115] Although there are numerous causes of diarrhea, the major consequences of diarrheal diseases, resulting from excessive chloride transport are common to all, and include dehydration, acidosis, impaired growth and death.
[00116] Acute and chronic diarrheas represent a major medical problem in many areas of the world. Diarrhea is both a significant factor in malnutrition and the leading cause of death (5,000,000 deaths/year) in children less than five years old.
[00117] Secretory diarrheas are also a dangerous condition in patients of acquired immunodeficiency syndrome (AIDS) and chronic inflammatory bowel disease (IBD). 16 million travelers to developing countries from industrialized nations every year develop diarrhea, Fwiitri'te slb^liilpifid^nuliSbEbiifclsies of diarrhea varying depending on the country and area of travel.
[00118] Diarrhea in barn animals and pets such as cows, pigs and horses, sheep, goats, cats and dogs, also known as scours, is a major cause of death in these animals. Diarrhea can result from any major transition, such as weaning or physical movement, as well as in response to a variety of bacterial or viral infections and generally occurs within the first few hours of the animal's life.
[00119] The most common diarrhea causing bacteria is enterotoxogenic E-coli
(ETEC) having the K99 pilus antigen. Common viral causes of diarrhea include rotavirus and coronavirus. Other infectious agents include Cryptosporidium, giardia lamblia, and salmonella, among others.
[00120] Symptoms of rotaviral infection include excretion of watery feces, dehydration and weakness. Coronavirus causes a more severe illness in the newborn animals, and has a higher mortality rate than rotaviral infection. Often, however, a young animal may be infected with more than one virus or with a combination of viral and bacterial microorganisms at one time. This dramatically increases the severity of the disease.
[00121] Accordingly, there is a need for modulators of an ABC transporter activity, and compositions thereof, that can be used to modulate the activity of the ABC transporter in the cell membrane of a mammal.
[00122] There is a need for methods of treating ABC transporter mediated diseases using such modulators of ABC transporter activity.
[00123] There is a need for methods of modulating an ABC transporter activity in an ex vivo cell membrane of a mammal.
[00124] There is a need for modulators of CFTR activity that can be used to modulate the activity of CFTR in the cell membrane of a mammal.
[00125] There is a need for methods of treating CFTR-mediated diseases using such modulators of CFTR activity.
[00126] There is a need for methods of modulating CFTR activity in an ex vivo cell membrane of a mammal. f
SUMMARY OF THE INVENTION
[00127] It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ABC transporter P©vly/ OiMi€hp'oiϊi® BiI fie general formula I:
Figure imgf000008_0001
I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, X, and m are described generally and in classes and subclasses below.
[00128] These compounds and pharmaceutically acceptable compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntingdon, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease, Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, and Sjogren's disease.
DETAILED DESCRIPTION OF THE INVENTION 1. General Description of the Invention:
[00129] The present invention relates to a method of modulating ABC transporter activity comprising the step of contacting said ABC transporter with a compounds of formula I:
Figure imgf000009_0001
I or a pharmaceutically acceptable salt thereof, wherein: Each R1 is independently R', halo, NO2, or CN; Each R2 is independently -XR';
Each X is independently a bond or is an optionally substituted Ci .(, alkylidene chain wherein up to two methylene units of X are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR'NRS -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, Or -NR5SO2NR'-;
Each R' is independently selected from hydrogen or an optionally substituted group selected from a C1-S aliphatic group, a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic or tricyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R' are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each R' group other than hydrogen is optionally substituted with 1-3 of -WRW.
Each m is independently 0-4;
Each R3 is independently H or a C1-8 aliphatic group optionally substituted with -X-RA and wherein up to two methylene units of the R3 aliphatic group may be replaced by -CO-, -CH2S-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR5-, -SO2NR5-, -NR5SO2-, or -NR5SO2NR'-;
Each RA is independently R', halo, NO2, or CN; PCT^MiSRtKB (όpό'lϊpϋiϊϊfclialkyl, (heterocycloaliphatic)alkyl, aralkyl, or heteroaralkyl wherein the alkyl portion of R4 is optionally substituted with R5 and wherein up to two methylene units of the alkyl portion of R4 may be replaced by -CO-, -CS-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-, and the cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl portions of R4 are optionally substituted with 1-3 of -WRW, or R4 is RB, or
R3 and R4 together with the nitrogen to which they are attached may form a 5 to 7 membered heterocycloaliphatic optionally substituted with 1 to 3 R';
RB is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally fused with an aryl or heteroaryl, wherein RB attaches to the nitrogen atom of the core structure at the cycloaliphatic or heterocycloaliphatic ring, and RB is optionally substituted with 1-3 of -WRW;
Each R5 is independently aryl, heteroaryl, Ci-8 aralkyl, or Ci-8 heteroaralkyl wherein the alkyl portion of R5 is optionally substituted with Rw and wherein up to two methylene units of the alkyl portion of R5 may be replaced by -CO-, -CS-, -CONR'-, -CONR5NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR5-, -NR5NR'-, -NR'NR'CO-, -NR5CO-, -S-, -SO-, -SO2- , -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-, and the aryl or heteroaryl portions of R5 are optionally substituted with 1-3 of-WRw;
Each W is independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR5-, -CONR5NR5-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR5-, -OCONR5-, -NR'NR'-, -NR'NR'CO-, -NR5CO-, -S-, -SO-, -SO2-, -NR5-, -SO2NR5-, -NR5SO2-, or -NR5SO2NR'-; and
Each Rw is independently R', halo, NO2, CN, CF3, -O(C1-4alkyl), -OCF3, or phenyl that is optionally substituted with 1-3 halo, haloalkyl, alkoxy, or aliphatic;
Provided that the compounds do not include, at the 5 position of the indole, the groups: -C(0)-(optionally substituted piperidinyl)-CH2-(optionally substituted phenyl), or -C(O)-(optionally substituted piperaziny I)-(C i.4alkyl)-(optionally substituted phenyl). 2. Compounds and Definitions:
[00130] Compounds of this invention include those described generally above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. P CΛ ..'['OMiSIJ la ..•'■ 'ϊiεiΛϊΞllIBC-transporter" as used herein means an ABC-transporter protein or a fragment thereof comprising at least one binding domain, wherein said protein or fragment thereof is present in vivo or in vitro. The term "binding domain" as used herein means a domain on the ABC-transporter that can bind to a modulator. See, e.g., Hwang, T. C. et al, J. Gen. Physiol. (1998): 111(3), 477-90.
[00132] The term "CFTR" as used herein means cystic fibrosis transmembrane conductance regulator or a mutation thereof capable of regulator activity, including, but not limited to, ΔF508 CFTR and G551D CFTR (see, e.g., http://www.genet.sickkids.on.ca/cftr/, for CFTR mutations).
[00133] The term "modulating" as used herein means increasing or decreasing, e.g. activity, by a measurable amount. Compounds that modulate ABC Transporter activity, such as CFTR activity, by increasing the activity of the ABC Transporter, e.g., a CFTR anion channel, are called agonists. Compounds that modulate ABC Transporter activity, such as CFTR activity, by decreasing the activity of the ABC Transporter, e.g., CFTR anion channel, are called antagonists. An agonist interacts with an ABC Transporter, such as CFTR anion channel, to increase the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding. An antagonist interacts with an ABC Transporter, such as CFTR, and competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor to decrease the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
[00134] The phrase "treating or reducing the severity of an ABC Transporter mediated disease" refers both to treatments for diseases that are directly caused by ABC Transporter and/or CFTR activities and alleviation of symptoms of diseases not directly caused by ABC Transporter and/or CFTR anion channel activities. Examples of diseases whose symptoms may be affected by ABC Transporter and/or CFTR activity include, but are not limited to, Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic FEff^rQnalrJoϊSβlaToQΪI'SfSiilβδitli, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease, Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, and Sjogren's disease.
[00135] For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[00136] As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
[00137] As used herein the term aliphatic encompasses the terms alkyl, alkenyl, and alkynyl.
[00138] The term "alkylidene chain" or "alkylidene" refers to a straight or branched carbon chain that may be fully saturated, e.g., alkyl, or have one or more units of unsaturation, e.g., alkenyl or alkynyl, and has two points of attachment to the rest of the molecule. The term "spirocycloalkylidene" refers to a carbocyclic ring that may be fully saturated or have one or more units of unsaturation and has two points of attachment from the same ring carbon atom to the rest of the molecule.
[00139] As used herein, an "alkyl" group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms. An alkyl group can be straight or branched. Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, and 2-ethylhexyl. An alkyl group can be optionally substituted with one or more substituents such as cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a ring together with the atom(s) to which they are bound), aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, acyl, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfmyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl,
- H - FMttamidelJSpycbatnαPiMpblldllyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, oxo, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, or heteroaralkylcarbonylamino.
[00140] As used herein, an "alkenyl" group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl. An alkenyl group can be optionally substituted with one or more substituents such as cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a ring together with the atom(s) to which they are bound), aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, acyl, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl.cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, oxo, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl- carbonylamino, heterocycloalkyl-alkylcarbonylamino, heteroarylcarbonylamino, or heteroaralkylcarbonylamino .
[00141] As used herein, an "alkynyl" group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and has at least one triple bond. An alkynyl group can be straight or branched. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl. An alkynyl group can be optionally substituted with one or more substituents such as cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a ring together with the atom(s) to which they are bound), aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, acyl, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl.cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, amino, nitro, carboxy, cyano, oxo, halo, hydroxy, sulfo, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, cycloalkyl-alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heterocycloalkyl-carbonylamino, heterocycloalkyl- FέlEyllarSlil^Riiifey'netSfiKpSiiHbnylamino, or heteroaralkylcarbonylamino.
[00142] As used herein, an "amino" group refers to -NRXRY wherein each of Rx and Rγ is independently hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl, or heteroaralkyl each of which are defined herein and are optionally substituted. When the term "amino" is not the terminal group (e.g., alkylcarbonylamino), it is represented by -NRX-. Rx has the same meaning as defined above.
[00143] As used herein, an "aryl" group used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl" refers to phenyl, naphthyl, or a benzofused group having 2 to 3 rings. For example, a benzofused group includes phenyl fused with one or two C4- 8 carbocyclic moieties, e.g., 1, 2, 3, 4-tetrahydronaphthyl, indanyl, or fluorenyl. An aryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, , alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, sulfonyl (such as alkylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[00144] As used herein, an "aralkyl" group refers to an alkyl group (e.g., a Ci-4 alkyl group) that is substituted with an aryl group. Both "alkyl" and "aryl" are defined herein. An example of an aralkyl group is benzyl. An "heteroaralkyl" group refers to an alkyl group that is substituted with a heteroaryl. Both "alkyl" and "heteroaryl" are defined herein.
[00145] As used herein, a "cyclcoaliphatic" group encompasses a "cycloalkyl" group and a "cycloalkenyl" group.
[00146] As used herein, a "cycloalkyl" group refers to a saturated carbocyclic mono- or bicyclic (fused or bridged) ring of 3-10 (e.g., 5-10) carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, and bicyclo[3.3.2.]decyl, and adamantyl. A "cycloalkenyl" group, as used herein, refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4-
Figure imgf000015_0001
S! SbSi double bond. Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, bicyclo[2.2.2]octenyl, and bicyclo[3.3.1]nonenyl. A cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalky^alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalky^carbonylamino, (heterocycloalky^alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[00147] A bicyclicaliphatic ring system encompasses bridged and fused cycloaliphatic ring systems which can be substituted with the substituents of a cycloaliphatic.
[00148] As used herein, the term heterocycloaliphatic encompasses a heterocycloalkyl group and a heterocycloalkenyl group.
[00149] As used herein, a "heterocycloalkyl" group refers to a 3- to 10-membered mono- or bicylic (fused or bridged) (e.g., 5- to 10-membered mono- or bicyclic) saturated ring structure, in which one or more of the ring atoms is a heteroatom, e.g., N, O, or S. Examples of a heterocycloalkyl group include piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuryl, dioxolanyl, oxazolidinyl, isooxazolidinyl, morpholinyl, octahydro-benzofuryl, octahydro- chromenyl, octahydro-thiochromenyl, octahydro-indolyl, octahydro-pyrindinyl, decahydro- quinolinyl, octahydro-benzo[έ]thiopheneyl, 2-oxa-bicyclo[2.2.2]octyl, 1 -aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03'7]nonyl. A monocyclic heterocycloalkyl group may be fused with a phenyl moiety such as tetrahydroisoquinoline. A "heterocycloalkenyl" group, as used herein, refers to a mono- or bicylic (e.g., 5- to 10-membered mono- or bicyclic) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom, e.g., N, O, or S. A heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl (such as a benzimidazolidinyl), (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or
Figure imgf000016_0001
.fδrϋifflgϋdibther with the atom(s) to which they are bound), cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkytyalkylcarbonylamino, arylcarbonylamino, aralkylcarbonylaniino, (heterocycloalky^carbonylamino, (heterocycloalkytyalkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
[00150] A bicyclicheteroaliphatic ring system encompasses bridged and fused cycloheteroaliphatic ring systems which can be substituted with the substituents of a heterocycloaliphatic.
[00151] A "heteroaryl" group, as used herein, refers to a monocyclic, bicyclic, or tricyclic ring structure having 4 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom, e.g., N, O, or S and wherein one ore more rings of the bicyclic or tricyclic ring structure is aromatic. A heteroaryl group includes a benzofused ring system having 2 to 3 rings. For example, a benzofused group includes phenyl fused with one or two C4-8 heterocyclic moieties, e.g., indolinyl and tertahydoquinolinyl. Some examples of heteroaryl are azetidinyl, pyridyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, tetrazolyl, benzofuryl, isoquinolinyl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, and benzo[l,3]dioxole. A heteroaryl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkytyalkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalky^carbonylamino, (heterocycloalkyOalkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. A "heteroaralkyl" group, as used herein, refers to an alky] group (e.g., a Ci-4 alkyl group) that is substituted with a heteroaryl group. Both "alkyl" and "heteroaryl" have been defined above.
[00152] As used herein, "cyclic moiety" includes cycloalkyl, heterocycloalkyl, FfijElSlkeif'l^ihEtffflβfSSlil^K^Ilyl, or heteroaryl, each of which has been defined previously.
[00153] As used herein, an "acyl" group refers to a formyl group or alkyl-C(=O)- where "alkyl" has been defined previously. Acetyl and pivaloyl are examples of acyl groups.
[00154] As used herein, a "carbamoyl" group refers to a group having the structure
-O-CO-NRXRY or -NRX-CO-O-RZ wherein Rx and Rγ have been defined above and Rz can be alkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl.
[00155] As used herein, a "carboxy" and a "sulfo" group refer to -COOH or
-COORX and -SO3H or -SO3RX, respectively.
[00156] As used herein, an "alkoxy" group refers to an alkyl-O- group where
"alkyl" has been defined previously.
[00157] As used herein, a "sulfoxy" group refers to -O-SO-RX or -SO-O-RX, where Rx has been defined above.
; [00158] As used herein, a "sulfonyl" group refers to -S(O)2-RX, wherein Rx has been defined above.
[00159] As used herein a "sulfinyl" group refers to -S(O)-RX, wherein Rx has been defined above.
[00160] As used herein a "sulfanyl" group refers to -S-Rx, wherein Rx has been defined above.
[00161] As used herein, a "halogen" or "halo" group refers to fluorine, chlorine, bromine or iodine.
[00162] As used herein, a "haloaliphatic" group refers to an aliphatic group substituted with 1-3 halogen. For instance, the term haloalkyl includes the group -CF3.
[00163] As used herein, a "sulfamoyl" group refers to the structure -S(O)2-NRXRY or -NRX~S(O)2-RZ wherein Rx, Rγ, and Rz have been defined above.
[00164] As used herein, a "sulfamide" group refers to the structure -NRX-S(O)2-
NRYRZ wherein Rx, Rγ, and Rz have been defined above.
[00165] As used herein, a "carbonylamino" group used alone or in connection with another group refers to an amido group such as -C(O)-NRX-, -NRX-C(O)-, and -C(O)-N(RX)2. For instance an alkylcarbonylamino includes alkyl-C(O)-NRx- and alkyl-NRx-C(O)-.
[00166] As used herein, a "urea" group refers to the structure -NRX-CO-NRYRZ and a "thiourea" group refers to the structure -NRX-CS-NRYRZ. Rx, Rγ, and Rz have been [00167] The phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted." As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. As described herein, the variables, such as R1, R2, R3, and R4, encompass specific groups, such as alkyl and aryl. Unless otherwise noted, each of the specific groups for the variables described herein with respect to foπnulae I, II, III, Ilia, and IV may be optionally substituted with one or more substituents described herein. Each substituent of a specific group is further optionally substituted with one to three of halo, cyano, alkoxy, hydroxyl, nitro, haloalkyl, and alkyl. For instance, an alkyl group may be substituted with alkylsulfanyl and the alkylsulfanyl may be optionally substituted with one to three of halo, cyano, alkoxy, hydroxyl, nitro, haloalkyl, and alkyl. As an additional example, an alkyl may be substituted with a (cycloalkyl)carbonylamino. The cycloalkyl portion of the (cycloalkyl)carbonylamino is optionally substituted with one to three of halo, cyano, alkoxy, hydroxyl, nitro, haloalkyl, and alkyl.
[00168] In general, the term "substituted," whether preceded by the term
"optionally" or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Specific substituents are described above in the definitions and below in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. A ring substituent, such as a heterocycloalkyl, may be bound to another ring, such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g., both rings share one common atom. As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
[00169] The phrase "stable or chemically feasible," as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
[00170] As used herein, an effective amount is defined as the amount required to Λ ~eii!9i':ϊliH€&ated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, New York, 537 (1970)/
[00171] As used herein, "patient" refers to a mammal, including a human.
[00172] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) confoπnational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a i3C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
3. Description of Exemplary Compounds:
[00173] In some embodiments of the present invention, the compounds of formula II are provided:
Figure imgf000019_0001
II or a pharmaceutically acceptable salt thereof, wherein: 1 L, Ii Ba^J&S iWgiR ,,:X',LJ€:|ald!,,i!n are as defined above;
Each AA and AB is independently aryl, heteroaryl, or heterocycloaliphatic each optionally substituted with 1-3 of -WRW;
Each Y1 and Y2 is independently a bond or is an optionally substituted Cj-6 alkylidene chain wherein up to two methylene units of the Ci-6 alkylidene chain are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR5CO-, -S-, -SO-, -SO2- , -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each W is independently a bond or is an optionally substituted C1 -6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR5-, -CONR'NR5-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR'CONR5-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR5-;
Each Rw is independently R5, halo, NO2, CN, CF3, -O(CMalkyl) or -OCF3; and
Each E is a independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of the Ci-6 alkylidene chain are optionally and independently replaced by -C(O)-, -CS-, -COCO-, CONR'-, -CONR'NR5-, -CO2-, -OCO-, -NR5CO2, -0-, -OCONR'-, -NR5NR'-, -NR'NR'CO-, -NR5CO-, -S-, -SO-, SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Provided that the compound is not
N- [ 1 -[(3 , 5 -difluoropheny l)methyl] -3 -[[(3 -ethylpheny l)methy 1] amino] -2-hydroxypropyl]- 1 -methyl-α-oxo- 1 H-indole-3 -acetamide,
2-(lH-indol-3-yl)-N-(2-morpholino-l-phenylethyl)-2-oxoacetamide, or N-(l,3-bis(benzylthio)propan-2-yl)-2-(lH-indol-3-yl)-2-oxoacetamide.
[00174] In some embodiments of the present invention, the compounds of formula
III are provided:
Figure imgf000021_0001
πi or a pharmaceutically acceptable salt thereof, wherein: Each R1, R2, R3, X, R', and m are as defined above;
Each R10 is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally substituted with 1-3 halo, haloalkyl, alkoxy, aliphatic, aryl, or heteroaryl, in which the aryl and heteroaryl are each optionally substituted with 1-3 of halo, alkoxy, haloalkyl, aliphatic; and
Each p is 0-3.
[00175] In some specific aspects, the compounds of formula III include the structure Ilia:
Figure imgf000021_0002
Ilia
Wherein each R1, R2, R3, X, R', and m are as defined above;
Ring Zz is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally substituted with 1-3 halo, haloalkyl, alkoxy, aliphatic, aryl, or heteroaryl, in which the aryl and heteroaryl are each optionally substituted with 1-3 of halo, alkoxy, haloalkyl, or aliphatic;
Each RE is independently halo, haloalkyl, alkoxy, or aliphatic; and
Each d is independently 0 to 3.
[00176] In other embodiments of the present invention, the compounds of formula
Figure imgf000022_0001
IV or a pharmaceutically acceptable salt thereof, wherein: Each R1, R2, R3, X, R', and m are as defined above;
Each Rπ is aryl or heteroaryl, each of which is optionally substituted with 1-3 halo, aliphatic, aryl, or heteroaryl; and
Each q is 0-3.
4. Description of Substituents
[00177] In one embodiment, R is hydrogen. Or, R is C1-C6 aliphatic. Exemplary
R includes C1-C6 alkyl e.g., methyl, ethyl, propyl, or butyl.
[00178] In one embodiment, R' is hydrogen.
[00179] In one embodiment, R' is a C1-C8 aliphatic group, optionally substituted with up to 3 substituents selected from halo, CN, CF3, CHF2, OCF3, or OCHF2, wherein up to two methylene units of said C1-C8 aliphatic is optionally replaced with -CO-, -CONH(C1~C4 alkyl)-, -CO2-, -OCO-, -N(Cl -C4 alkyl)CO2-, -O-, -N(C1-C4 alkyl)CON(Cl-C4 alkyl)-, -OCON(C1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO2N(C1-C4 alkyl)-, N(C1-C4 alkyl)SO2-, or -N(C1-C4 alkyI)SO2N(Cl-C4 alkyl)-.
[00180] In one embodiment, R' is a C 1-C4 alkyl or a C2-C4 alkenyl, optionally substituted with up to 3 substituents selected from halo, CN, CF3, CHF2, OCF3, or OCHF2, wherein up to two methylene units of said C1-C4 alkyl or a C2-C4 alkenyl is optionally replaced with -CO-, -CONH(C1-C4 alkyl)-, -CO2-, -OCO-, -N(C1-C4 alkyl)CO2-, -O-, -N(C1-C4 alkyl)CON(Cl-C4 alkyl)-, -OCON(C1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO2N(C1-C4 alkyl)-, N(C1-C4 alkyl)SO2-, or -N(C1-C4 alkyl)SO2N(Cl -C4 alkyl)-.
[00181] In one embodiment, R' is a C 1-C4 alkyl or a C2-C4 alkenyl, optionally SfsySstϊFutelM halo, CN, CF3, CHF2, OCF3, Or OCHF2.
[00182] In one embodiment, R' is a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF3, CHF2, OCF3, OCHF2, or C1-C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C 1-C4 alkyl)-, -CO2-, -OCO-, -N(C1-C4 alkyl)CO2-, -0-, -N(C1-C4 alkyl)CON(Cl-C4 alkyl)-, -OCON(C1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO2N(C1-C4 alkyl)-, N(C1-C4 alkyl)SO2- , or -N(C1-C4 alkyl)SO2N(Cl-C4 alkyl)-.
[00183] In one embodiment, R' is a 3-8 membered cycloalkyl ring independently selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF3, CHF2, OCF3, OCHF2, or C1-C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C 1-C4 alkyl)-, -CO2-, -OCO-, -N(C1-C4 alky I)CO2-, -0-, -N(C1-C4 alkyl)C0N(Cl-C4 alkyl)-, -OCON(C 1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO2N(C 1-C4 alkyl)-, N(C1-C4 alkyl)SO2-, or -N(C1-C4 alkyl)SO2N(Cl-C4 alkyl)-. Exemplary embodiments include optionally substituted cyclopropyl, cyclopentyl, or cyclohexyl.
[00184] In one embodiment, R' is a 3-8 membered saturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF3, CHF2, OCF3, OCHF2, or C1-C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C 1-C4 alkyl)-, -CO2-, -OCO-, -N(C1-C4 alkyl)CO2-, -0-, -N(Cl- C4 alkyl)C0N(Cl-C4 alkyl)-, -OCON(C 1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO2N(C1-C4 alkyl)-, N(C1-C4 alkyl)SO2-, or -N(C1-C4 alkyl)SO2N(Cl-C4 alkyl)-. Exemplary embodiments include optionally substituted tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, etc.
[00185] In one embodiment, R' is a 3-8 membered saturated monocyclic ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF3, CHF2, OCF3, OCHF2, or Cl- C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C1-C4 alkyl)-, -CO2-, -OCO-, -N(C1-C4 alkyl)CO2-, -0-, -N(C1-C4 alkyl)C0N(Cl-C4 alkyl)-, -OCON(C 1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(Cl -C4 alkyl)-, -SO2N(C 1-C4 alkyl)-, N(C1-C4 alkyl)SO2-, or -N(Cl -C4 alkyl)SO2N(Cl-C4 alkyl)-. PC:T.flJdϊ$ii|O 13 /liibffiiml$3iment, R' is an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF3, CHF2, OCF3, OCHF2, or C1-C6 alkyl, wherein up to two methylene units of said C1-C6 alkyl is optionally replaced with -CO-, -CONH(C 1-C4 alkyl)-, -CO2-, -OCO-, -N(C1-C4 alky I)CO2-, -0-, -N(C1-C4 alkyl)CON(Cl-C4 alkyl)-, -OCON(C 1-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO2N(C 1-C4 alkyl)-, N(C1-C4 alkyl)SO2-, or -N(C1-C4 alkyl)SO2N(Cl-C4 alkyl)-.
[00187] In one embodiment, two occurrences of R' are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R' is optionally substituted with up to 3 substituents selected from halo, CN, CF3, CHF2, OCF3, OCHF2, or C1-C6 alkyl, wherein up to two methylene .units of said C1-C6 alkyl is optionally replaced with -CO-, - CONH(C1-C4 alkyl)-, -CO2-, -OCO-, -N(C1-C4 alkyl)CO2-, -O-, -N(C1-C4 alkyl)C0N(Cl-C4 alkyl)-, -0C0N(Cl-C4 alkyl)-, -N(C1-C4 alkyl)CO-, -S-, -N(C1-C4 alkyl)-, -SO2N(C1-C4 alkyl)-, N(C1-C4 alky I)SO2-, or -N(C1-C4 alkyl)SO2N(Cl-C4 alkyl)-.
[00188] In several embodiments R3 is independently H or a Q.g aliphatic group optionally substituted with -X-RΛ. In several examples, R3 is H.
[00189] In some embodiments, R4 is (cycloaliphatic)alkyl,
(heterocycloaliρhatic)alkyl, aralkyl, or heteroaralkyl in which the alkyl portion of R4 is substituted with R5. In other embodiments, R4 is an aralkyl or a heteroaralkyl each optionally substituted with WRW.
[00190] In some embodiments, each R4 is Ci-8 aralkyl or Cj-8 heteroaralkyl wherein the alkyl portion of R4 is optionally substituted with R5 and wherein up to two methylene units of the alkyl portion of R4 may be replaced by -CO-, -CS-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, Or -NR5SO2NR'-, and the aryl or heteroaryl portions of R4 are optionally substituted with 1-3 of -WRW.
[00191] In some embodiments, R is Cj-8 aralkyl or C]-8 heteroaralky in which the aryl or heteroaryl portions of are optionally substituted with 1-3 of -WRW. R4 is a -(Ci-4 alkyl)- aryl in which the aryl is optionally substituted with 1-3 of -WRW. R4 is a -(Ci-4 alkyl)-aryl in which the aryl is substituted with 1-2 substituents independently selected from alkoxy, halo, liSjϋaϋdilkylcarbonyl . R4 is a -(Cμ alkyl)-heteroaryl in which the heteroaryl is optionally substituted with 1-3 of -WR . R is a -(Ci4 alkyl)-heteroaryl in which the heteroaryl is substituted with 1-2 substituents independently selected from alkoxy, halo, alkylcarbonylamino, aliphatic, alkylarylalkyl, and alkylcarbonyl.
[00192] In some embodiments, R4 is Ci-8 aralkyl or Ci-8 heteroaralky in which the aryl or heteroaryl portions are optionally substituted with 1-3 of -WRW and wherein one or two non-adjacent methylene units in the Q^alkyl portion are optionally and independently replaced by -O-, -NR'-, -S-, -SO2-, -COO-, or -CO-. R4 is Ci-8 aralkyl or Ci-8 heteroaralky in which the aryl or heteroaryl portions are optionally substituted with 1-3 of -WRW and wherein one or two non-adjacent methylene units in the Ci-4 alkyl portion are optionally and independently replaced by O, NR', or S.
[00193] In some embodiments, R4 is cycloaliphatic or a heterocycloaliphatic, each of which is optionally substituted with 1-3 -WRW. In several examples, R4 is a monocyclic cycloaliphatic or a monocyclic heterocyclicaliphatic. In some examples, R4 is cyclohexyl, cyclopentyl, cyclobutyl, or cyclopropyl, each of which is optionally substituted with 1-3 of -WRW. In several other examples, R4 is cycloaliphatic and R4 is substituted with an optionally substituted aryl. More specific examples of R4 include cyclohexyl, cyclopentyl, or cyclopropyl that is monosubstituted with an optionally substituted phenyl.
[00194] In other examples, R4 is piperidinyl, or tetrahydropyrrolyl, each of which is optionally substituted with 1-3 of -WRW. In other examples, R4 is a bicyclicaliphatic or a bicyclicheteroaliphatic, each of the bicyclicaliphatic or the bicyclicheteroaliphatic is optionally substituted with 1-3 of -WRW. R4 is a bicyclicaliphatic optionally substituted with 1-3 of -WRW. R4 is noboraanyl optionally substituted with 1-3 of -WRW. Alternatively, R4 is tropane optionally substituted with 1-3 of -WRW.
[00195] In some embodiments, R5 is an optionally substituted Ci-4 aliphatic group.
[00196] In several embodiments, RB is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally fused with an aryl or heteroaryl wherein RB attaches to the amino nitrogen atom of core structure at any chemically viable position on the cycloaliphatic or heterocycloaliphatic ring, and RB is optionally substituted with 1-3 of -WRW.
[00197] In several embodiments RB is
Figure imgf000026_0001
where RB is optionally substituted with 1 -3 -WRW at any chemically viable position, wherein -WRW is defined above. For example, RB is
Figure imgf000026_0002
[00200] In several alternative embodiments, RB is indolizinyl, indolyl, indolinyl, benzo[Z>]furyl, benzo[δ]thiophenyl, hydroindazolyl, benzimidazolyl, benzthiazolyl, purinyl, or indenyl; each of which is optionally substituted with 1-3 alkoxy, aliphatic, halo, or alkylcarbonyl.
[00201] In other embodiments, W is a bond or is an optionally substituted Cue alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by -O-, -NR'-, -S-, -SO2-, -COO-, or -CO-. In some embodiment, Rw is R' or halo. In still other embodiments, each occurrence of WRW is independently -Ci-3alkyl, -O(C1-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, or -COOR', -COR', -O(CH2)2N(R')(R'), -O(CH2)N(R')(R'), -CON(R')(R')> -(CH2)2OR\ -(CH2)OR', optionally substituted monocyclic or bicyclic aromatic ring, optionally substituted arylsulfonyl, optionally substituted 5-membered heteroaryl ring, -N(R')(R'), -(CH2)2N(R')(R'), or -(CH2)N(R1XR'). W is a bond and R1 is halo or R'.
[00202] In some embodiments, m is 1 or 2.
[00203] In some embodiments, m is 0. Or, m is 1. Or, m is 2. In some embodiments, m is 3. In yet other embodiments, m is 4.
[00204] In some embodiments, R2 is hydrogen. Or, R2 is an optionally substituted
Ci-8 aliphatic group. In some embodiments, R2 is optionally substituted Q-4 aliphatic. P C T[tf(MϊS|OIE /ImlbϊSrMMdϊnient of the present invention, each R1 is simultaneously hydrogen. In another embodiment, R2 and R3 are both simultaneously hydrogen.
[00206] In another embodiment, R1 is X-RA, wherein X is -SO2NR'-, and RA is R'.
[00207] In some embodiments, X is a bond or is an optionally substituted Ci-6 alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by -O-, -NR-, -S-, -SO2-, -COO-, or -CO-. In some embodiments, RA is R' or halo. In still other embodiments, each occurrence of XRA is independently -Ci-3alkyl, -O(Ci-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, or -COOR', -COR', -O(CH2)2N(R)(R'), -0(CH2)N(R)(R'), -CON(R)(R'), -(CH2J2OR', -(CH2)OR', optionally substituted phenyl, -N(R)(R'), -(CH2)2N(R)(R'), or -(CH2)N(R)(R').
[00208] In some embodiments, R3 is hydrogen. In certain other embodiment, R3 is
CM straight or branched aliphatic.
[00209] In some embodiments, Rw is selected from hydrogen, aliphatic, alkylcarbonylamino, or alkoxy.
[00210] In some embodiments, each occurrence of WRW is independently
-Ci-3alkyl, -O(Ci-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, -SO2NH2, -COOR', -COR', -O(CH2)2N(R)(R'), -0(CH2)N(R)(R'), -CON(R)(R'), -(CH2)2OR\ -(CH2)OR', optionally substituted monocyclic or bicyclic aromatic ring, optionally substituted arylsulfonyl, optionally substituted 5-membered heteroaryl ring, -N(R)(R'), -(CH2)2N(R)(R5), or -(CH2)N(R)(R'). In other embodiments, -WRW is selected from aliphatic, alkoxy, or alkylcarbonylamino.
[00211] In several embodiments R10 in formula III is cycloaliphatic. Examples of
R10 include cyclohexyl, cyclopropyl, cyclopentyl, or cyclobutyl, each of which is optionally substituted with 1-3 aliphatic, aryl, or heteroaryl. If R10 is substituted with aliphatic, halo, aryl, or heteroaryl, said aliphatic, halo, aryl, or heteroaryl can be optionally substituted with 1-3 alkoxy, halo, or aliphatic.
[00212] In several other embodiments, R10 is heterocycloaliphatic. Examples of
R10 include tetrahydrofuryl, piperidinyl, or pyrrolidinyl, each of which is optionally substituted with 1-3 aliphatic, halo, aryl, or heteroaryl. IfR10 is substituted with aliphatic, halo, aryl, or heteroaryl, said aliphatic, halo, aryl, or heteroaryl can be optionally substituted with 1-3 alkoxy, halo, or aliphatic.
[00213] In several other embodiments, R10, in formula III, is one selected from:
Figure imgf000028_0001
[00214] In several embodiments, R11 is an optionally substituted aryl or heteroaryl.
In several other embodiments R11 is optionally substituted with 1-3 substituents independently selected from halo, aliphatic, aryl, heteroaryl, and alkoxy. IfR11 is substituted with an aliphatic, aryl, heteroaryl, or alkoxy, said aliphatic, aryl, heteroaryl, or alkoxy can be optionally substituted with 1-3 alkoxy, aliphatic, or halo.
[00215] In several additional embodiments, R11 is one selected from:
Figure imgf000028_0002
[00216] In still further embodiments, R3 and R4 together form a 5 to 7 membered heterocycloaliphatic optionally substituted with 1-3 of -WR w . In specific embodiments, R and R4 together form an optionally substituted piperidine or an optionally substituted piperazine.
[00217] Representative compounds of the invention include:
Figure imgf000029_0001
Figure imgf000030_0001
5. General Synthetic Schemes
[00218] Compounds of formula I can be prepared by methods known in the art.
Schemes 1 and 2 below illustrate an exemplary synthetic method for compounds of formula I.
Scheme 1:
Figure imgf000030_0002
Scheme 2:
Figure imgf000030_0003
[00219] The starting indole oxalylchlorides and indoloxalic acids are
Figure imgf000031_0001
[00220] Exemplary compounds of the present invention prepared according to
Schemes 1 and 2 are recited below in the Examples.
5. Uses, Formulation and Administration Pharmaceutically acceptable compositions
[00221] As discussed above, the present invention provides compounds that are useful as modulators of ABC transporters and thus are useful in the treatment of disease, disorders or conditions such as Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease (due to Prion protein processing defect), Fabry disease and Straussler-Scheinker syndrome.
[00222] Accordingly, in another aspect of the present invention, pharmaceutically acceptable compositions are provided, wherein these compositions comprise any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
[00223] It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative or a prodrug thereof. According to the present invention, a pharmaceutically acceptable derivative or a prodrug includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative I^EcffupdyalmlHSMratiitficiipL^nt in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
[00224] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A "pharmaceutically acceptable salt" means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
[00225] Pharmaceutically acceptable salts are well known in the art. For example,
S. M. Berge, et at. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci.4alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate. P C T ,[0'(H-SHS]013 /ySffiacliibMilabove, the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D.B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York, the contents of each of which is incorporated by reference herein, disclose various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
Uses of Compounds and Pharmaceutically Acceptable Compositions
[00227] In yet another aspect, the present invention provides a method of treating Mon| IisUsSii €iriyδliiiiiHplicated by ABC transporter activity. In certain embodiments, the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of ABC transporter activity, the method comprising administering a composition comprising a compound of formula (I) to a subject, preferably a mammal, in need thereof.
[00228] In certain preferred embodiments, the present invention provides a method of treating Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation- Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease (due to Prion protein processing defect), Fabiy disease, Straussler-Scheinker disease, secretory diarrhea, polycystic kidney disease, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome, comprising the step of administering to said mammal an effective amount of a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
[00229] According to an alternative preferred embodiment, the present invention provides a method of treating cystic fibrosis comprising the step of administering to said mammal a composition comprising the step of administering to said mammal an effective amount of a composition comprising a compound of foπnula (I), or a preferred embodiment thereof as set forth above.
[00230] According to the invention an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary iφόid^4SPlΛfrdciϊSgi:iB?iObncies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofϊbrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease, Fabry disease, Straussler-Scheinker disease, secretory diarrhea, polycystic kidney disease, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.
[00231] The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Lipid processing deficiencies, such as Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, Lysosomal storage diseases, such as I-cell disease/Pseudo-Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, several polyglutamine neurological disorders asuch as Huntington, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, and Myotonic dystrophy, as well as Spongiform encephalopathies, such as Hereditary Creutzfeldt- Jakob disease, Fabry disease, Straussler-Scheinker disease, secretory diarrhea, polycystic kidney disease, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome. i»" L. il
Figure imgf000036_0001
required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors known in the medical arts. The term "patient", as used herein, means an animal, for example, a mammal, and more specifically a human.
[00233] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[00234] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, 'emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. P1 C T{d'ft-i!-{ijO Gi /itήfeϊ;&ibϊi|ff%aratiόns, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[00236] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00237] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[00238] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[00239] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium Pi^pSateiyiRillEpfitfeBeStBffirs such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[00240] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
[00241] The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[00242] Dosage forms for topical or transdermal administration of a compound of ffi£iii?enlJfiBfi©/όϊMfe!H.ϊsiijf)iiites5 creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdeπnal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[00243] As described generally above, the compounds of the invention are useful as modulators of ABC transporters. Thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of ABC transporters is implicated in the disease, condition, or disorder. When hyperactivity or inactivity of an ABC transporter is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a "ABC transporter-mediated disease, condition or disorder". Accordingly, in another aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where hyperactivity or inactivity of an ABC transporter is implicated in the disease state.
[00244] The activity of a compound utilized in this invention as a modulator of an
ABC transporter may be assayed according to methods described generally in the art and in the Examples herein.
[00245] It will also be appreciated that the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a lpaiicfikr Ifsiyiiiϊ-.coiiSyiisiiMllnown as "appropriate for the disease, or condition, being treated".
[00246] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[00247] The compounds of this invention or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the present invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. In still another aspect, the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
[00248] Another aspect of the invention relates to modulating ABC transporter activity in a biological sample or a patient (e.g., in vitro or in vivo), which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound. The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[00249] Modulation of ABC transporter activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of ABC transporters in biological and pathological Sntfmέnltt Eml'MS c6ήϊ|)Pa®i'Jvlluation of new modulators of ABC transporters.
[00250] In yet another embodiment, a method of modulating activity of an anion channel in vitro or in vivo, is provided comprising the step of contacting said channel with a compound of formula (I). In preferred embodiments, the anion channel is a chloride channel or a bicarbonate channel. In other preferred embodiments, the anion channel is a chloride channel.
[00251] According to an alternative embodiment, the present invention provides a method of increasing the number of functional ABC transporters in a membrane of a cell, comprising the step of contacting said cell with a compound of formula (I). The term "functional ABC transporter" as used herein means an ABC transporter that is capable of transport activity. In preferred embodiments, said functional ABC transporter is CFTR.
[00252] According to another preferred embodiment, the activity of the ABC transporter is measured by measuring the transmembrane voltage potential. Means for measuring the voltage potential across a membrane in the biological sample may employ any of the known methods in the art, such as optical membrane potential assay or other electrophysiological methods.
[00253] The optical membrane potential assay utilizes voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00254] These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC2(3), and a fluorescent phospholipid, GC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor. Changes in membrane potential (Vm) cause the negatively charged DiSBAC2(3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly. The changes in fluorescence emission can be monitored using VIPR™ II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates.
[00255] In another aspect the present invention provides a kit for use in measuring the activity of a ABC transporter or a fragment thereof in a biological sample in vitro or in vivo RKpliS'inl-^iyESdliipόs^lffiSbS'fiBsing a compound of formula (I) or any of the above embodiments; and (ii) instructions for a) contacting the composition with the biological sample and b) measuring activity of said ABC transporter or a fragment thereof. In one embodiment, the kit further comprises instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said ABC transporter or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the ABC transporter in the presence of the additional compound with the density of the ABC transporter in the presence of a composition of formula (I). In preferred embodiments, the kit is used to measure the density of CFTR.
[00256] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
6. Examples
[00257] Synthesis of exemplary compounds are described in the Examples below.
Example 1; N-Benzhvdryl-2-(lH-indoI-3-vI)-2-oxo-acetamide
[00258] N-Benzhydryl-2-(lH-indol-3-yl)-2-oxo-acetamide was synthesized following scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and C,C-diphenyl- methylamine. Yield (52 %). HPLC ret. time 3.59 min, 10-99 % CH3CN, 5 min run; 1H NMR (400 MHz, DMSO-J6) δ 12.26 (s, IH), 9.56 (d, J = 9.1 Hz, IH), 8.56 (d, J = 3.2 Hz, IH), 8.22 (m, IH), 7.54 (m, IH), 7.43-7.26 (m, 12H), 6.32 (d, J = 9.1 Hz, IH); ESI-MS 355.5 m/z (MH+).
Example 2; 2-(lH-IndoI-3-vD-2-oxo-N-phenethyl-acetamide
[00259] 2-(lH-Indol-3-yl)-2-oxo-N-phenethyl-acetamide was synthesized following scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and phenethylamine. Yield (61 %). HPLC ret. time 3.17 min, 10-99 % CH3CN, 5 min run; 1H NMR (400 MHz, DMSO-J6) δ 12.23 (s, IH), 8.79 (t, J = 5.9 Hz, IH), 8.67 (s, IH), 8.23 (m, IH), 7.53 (m, IH), 7.33-7.19 (m, 7H), 3.47 (m, 2H), 2.85 (t, J = 7.4 Hz, 2H); ESI-MS 293.3 m/z (MH+).
Example 5: N,N-Dibenzyl-2-(lH-indol-3-yl)-2-oxo-acetamide
[00260] N,N-Dibenzyl-2-(lH-indol-3-yl)-2-oxo-acetamide was synthesized following scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and dibenzylamine. Yield (58 %). HPLC ret. time 3.52 min, 10-99 % CH3CN, 5 min run; 1H NMR (400 MHz, P®Sl»W6pϊøθ!€|d/i;§ililiiHgIH), 8.18 (d, J = 3.3 Hz, IH), 8.11 (d, J = 7.6 Hz, IH), 7.54 (m, IH), 7.43-7.39 (m, 2H), 7.35-7.22 (m, 10H), 4.54 (s, 2H), 4.41 (s, 2H); ESI-MS 369.3 m/z (MH+).
Example 10: 2-(l-Methyl-lH-indol-3-yI)-2-oxo-N-phenethyI-acetamide
[00261] 2-(l -Methyl-lH-indol-3-yl)-2-oxo-N-phenethyl-acetamide was synthesized following scheme II above starting from (l-methyl-lH-indol-3-yl)-oxo-acetic acid and phenethylamine. Yield (61 %). HPLC ret. time 3.38 min, 10-99 % CH3CN, 5 min run; 1H NMR (400 MHz, DMSCMO δ 8.80 (t, J = 5.9 Hz, IH), 8.73 (s, IH), 8.25 (m, IH), 7.60 (m, IH), 7.36-7.20 (m, 7H), 3.91 (s, 3H), 3.47 (m, 2H), 2.86 (t, J = 7.4 Hz, 2H); ESI-MS 307.3 m/z (MH+).
Example 12: N-Benzhvdryl-2-(l-methyl-lH-indol-3-yI)-2-oxo-acetamide
[00262] N-Benzhydryl-2-(l-methyl-lH-indol-3-yl)-2-oxo-acetamide was synthesized following scheme II above starting from (1 -methyl- lH-indol-3-yl)-oxo-acetic acid and CC-diphenyl-methylamine. Yield (11 %). HPLC ret. time 3.79 min, 10-99 % CH3CN, 5 mirrrun; 1H NMR (400 MHz, DMSO-J6) δ 9.56 (d, J = 9.1 Hz, IH), 8.65 (s, IH), 8.24 (m, IH), 7.61 (m, IH), 7.43-7.26 (m, 12H), 6.32 (d, J = 9.1 Hz, IH), 3.90 (s, 3H); ESI-MS 369.1 m/z (MH+).
Example 14 : N-Benzyl-2-(lH-indoI-3-yl)-N-methyI-2-oxo-acetamide
[00263] N-Benzyl-2-(lH-indol-3-yl)-N-methyl-2-oxo-acetamide was synthesized following scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and benzyl-methyl- amine. Yield (54 %). HPLC ret. time 2.96 min, 10-99 % CH3CN, 5 min run; 1H NMR (400 MHz, DMSO-J6) δ 12.35 (s, IH), 8.25 (s, 0.5H), 8.13-8.11 (m, 1.5H), 7.54 (m, IH), 7.44-7.23 (m, 7H), 4.68 (s, IH), 4.47 (s, IH), 2.88 (s, 1.5H), 2.85 (s, 1.5H); ESI-MS 293.3 m/z (MH+).
Example 15: N,N-Dibenzyl-2-(l-methyI-lH-indoI-3-vD-2-oxo-acetamide
[00264] N,N-Dibenzyl-2-(l-methyl-lH-indol-3-yl)-2-oxo-acetamide was synthesized following scheme II above starting from (1 -methyl- lH-indol-3-yl)-oxo-acetic acid and dibenzylamine. Yield (70 %). HPLC ret. time 3.70 min, 10-99 % CH3CN, 5 min run; 1H NMR (400 MHz, DMSO-J6) δ 8.28 (s, IH), 8.12 (d, J = 7.7 Hz, IH), 7.61 (d, J = 8.1 Hz, IH), 7.43-7.25 (m, 12H), 4.55 (s, 2H), 4.40 (s, 2H), 3.93 (s, 3H); ESI-MS 383.3 m/z (MH+). ι-2-(lH-indoI-3-yl)-2-oxo-acetamide
[00265] N-(2,2-Diphenylethyl)-2-(lH-indol-3-yl)-2-oxo-acetamide was synthesized following the scheme I above starting from (lH-indol-3-yl)-oxo-acetyl chloride and 2,2-diphenyl-ethylamine. Yield (48 %). HPLC ret. time 3.55 min, 10-99 % CH3CN, 5 min run; 1H NMR (400 MHz, DMSO-^6) δ 12.22 (s, IH), 8.70 (t, J = 5.9 Hz, IH), 8.50 (s, IH), 8.17 (m, IH), 7.52 (m, IH), 7.36-7.18 (m, 12H), 4.43 (t, J = 8.0 Hz, IH), 3.90 (dd, J = 8.0, 6.0 Hz, 2H); ESI-MS 369.3 m/z (MH+).
[00266] A person reasonably skilled in the chemical arts can use the examples and schemes above to synthesize compounds of the present invention, including the compounds in Table 1.
[00267] Set forth below is the characterizing data for compounds of the present invention prepared according to the above Examples.
Table 2 Exemplary compounds of Formulae (I, II, III and IV)
Figure imgf000044_0001
Figure imgf000045_0001
* obtained with a 3 min HPLC method
7. Assays for Detecting and Measuring ΔF508-CFTR Correction Properties of Compounds
Membrane potential optical methods for assaying ΔF508-CFTR modulation properties of compounds
[00268] The optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00269] These voltage sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC2(3), and a fluorescent phospholipid, CC2-DMPE, which is attached to the outer leaflet of the plasma membrane and acts as a FRET donor. Changes in membrane potential (Vm) cause the negatively charged DiSBAC2(3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly. The changes in fluorescence emission were monitored using VIPR™ II, which is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-well microtiter plates.
Identification of Correction Compounds
[00270] To identify small molecules that correct the trafficking defect associated
Figure imgf000046_0001
assay format was developed. The cells were incubated in serum-free medium for 16 hrs at 37 0C in the presence or absence (negative control) of test compound. As a positive control, cells plated in 384-well plates were incubated for 16 hrs at 27 0C to "temperature-correct" ΔF508-CFTR. The cells were subsequently rinsed 3X with Krebs Ringers solution and loaded with the voltage-sensitive dyes. To activate ΔF508-CFTR, 10 μM forskolin and the CFTR potentiator, genistein (20 μM), were added along with Cl'-free medium to each well. The addition of Cl"- free medium promoted Cl" efflux in response to ΔF508-CFTR activation and the resulting membrane depolarization was optically monitored using the FRET-based voltage-sensor dyes.
Identification of Potentiator Compounds
[00271] To identify potentiators of ΔF508-CFTR, a double-addition HTS assay format was developed. During the first addition, a Cl"-free medium with or without test compound was added to each well. After 22 sec, a second addition of Cl"-free medium containing 2 - 10 μM forskolin was added to activate ΔF508-CFTR. The extracellular Cl" concentration following both additions was 28 mM, which promoted Cl" efflux in response to ΔF508-CFTR activation and the resulting membrane depolarization was optically monitored using the FRET-based voltage-sensor dyes. Solutions
Bath Solution #1 : (in mM) NaCl 160, KCl 4.5, CaCl2 2, MgCl2 1, HEPES 10, pH 7.4 with NaOH.
Chloride-free bath solution: Chloride salts in Bath Solution #1 are substituted with gluconate salts.
CC2-DMPE: Prepared as a 10 mM stock solution in DMSO and stored at -2O0C. DiSBAC2(3): Prepared as a 10 mM stock in DMSO and stored at -200C.
Cell Culture
[00272] NIH3T3 mouse fibroblasts stably expressing ΔF508-CFTR are used for optical measurements of membrane potential. The cells are maintained at 37 0C in 5% CO2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, D-ME, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For all optical assays, the cells were seeded at 30,000/well in 384-well matrigel-coated plates and cultured for 2 hrs at 37 0C before culturing at 27 0C for 24 hrs. for the potentiator ss y. ψ ;ϊ5cr 3tiόn s ii 'iells are cultured at 270C or 37 °C with and without compounds for 16 - 24 hoursElectrophysiological Assays for assaying ΔF508-CFTR modulation properties of compounds
1. Ussing Chamber Assay
[00273] Ussing chamber experiments were performed on polarized epithelial cells expressing ΔF508-CFTR to further characterize the ΔF508-CFTR modulators identified in the optical assays. PRTΔF508-CFTR epithelial cells grown on Costar Snapwell cell culture inserts were mounted in an Ussing chamber (Physiologic Instruments, Inc., San Diego, CA), and the monolayers were continuously short-circuited using a Voltage-clamp System (Department of Bioengineering, University of Iowa, IA, and, Physiologic Instruments, Inc., San Diego, CA). Transepithelial resistance was measured by applying a 2-mV pulse. Under these conditions, the FRT epithelia demonstrated resistances of 4 KΩ/ cm2 or more. The solutions were maintained at 27 0C and bubbled with air. The electrode offset potential and fluid resistance were corrected using a cell-free insert. Under these conditions, the current reflects the flow of Cl" through ΔF508-CFTR expressed in the apical membrane. The Isc was digitally acquired using an MPlOOA-CE interface and AcqKnowledge software (v3.2.6; BIOPAC Systems, Santa Barbara, CA).
Identification of Correction Compounds
[00274] Typical protocol utilized a basolateral to apical membrane Cl" concentration gradient. To set up this gradient, normal ringer was used on the basolateral membrane, whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl" concentration gradient across the epithelium. All experiments were performed with intact monolayers. To fully activate ΔF508-CFTR, forskolin (10 μM) and the PDE inhibitor, IBMX (100 μM), were applied followed by the addition of the CFTR potentiator, genistein (50 μM).
[00275] As observed in other cell types, incubation at low temperatures of FRT cells stably expressing ΔF508-CFTR increases the functional density of CFTR in the plasma membrane. To determine the activity of correction compounds, the cells were incubated with 10 μM of the test compound for 24 hours at 37°C and were subsequently washed 3X prior to recording. The cAMP- and genistein-mediated Isc in compound-treated cells was normalized to the 270C and 37°C controls and expressed as percentage activity. Preincubation of the cells with the correction compound significantly increased the cAMP- and genistein-mediated Isc
Figure imgf000048_0001
Identification of Potentiator Compounds
[00276] Typical protocol utilized a basolateral to apical membrane Cl" concentration gradient. To set up this gradient, normal ringers was used on the basolateral membrane and was permeabilized with nystatin (360 μg/ml), whereas apical NaCI was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl" concentration gradient across the epithelium. All experiments were performed 30 min after nystatin permeabilization. Forskolin (10 μM) and all test compounds were added to both sides of the cell culture inserts. The efficacy of the putative ΔF508-CFTR potentiators was compared to that of the known potentiator, genistein.
Solutions
Basolateral solution (in mM): NaCl (135), CaCl2 (1.2), MgCl2 (1.2), K2HPO4 (2.4),
KHPO4 (0.6), N-2-hydroxyethylpiperazine-N'-2- ethanesulfonic acid (HEPES) (10), and dextrose (10). The solution was titrated to pH 7.4 with NaOH.
Apical solution (in mM): Same as basolateral solution with NaCl replaced with Na
Gluconate (135).
Cell Culture
[00277] Fisher rat epithelial (FRT) cells expressing ΔF508-CFTR (FRTΔF508-CFTR) were used for Ussing chamber experiments for the putative ΔF508-CFTR modulators identified from our optical assays. The cells were cultured on Costar Snapwell cell culture inserts and cultured for five days at 37 0C and 5% CO2 in Coon's modified Ham's F-12 medium supplemented with 5% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. Prior to use for characterizing the potentiator activity of compounds, the cells were incubated at 27 0C for 16 - 48 hrs to correct for the ΔF508-CFTR. To determine the activity of corrections compounds, the cells were incubated at 27 0C or 37 0C with and without the compounds for 24 hours.
2. Whole-cell recordings
[0001] The macroscopic ΔF508-CFTR current (IΛFSOS) in temperature- and test compound- corrected NIH3T3 cells stably expressing ΔF508-CFTR were monitored using the perforated- patch, whole-cell recording. Briefly, voltage-clamp recordings of IΛFSOS were performed at room temperature using an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc., Foster City, : a sampling frequency of 10 kHz and low-pass tiltereα at i kHz. Pipettes had a resistance of 5 - 6 MΩ when filled with the intracellular solution. Under these recording conditions, the calculated reversal potential for Cl" (Eci) at room temperature was -28 mV. All recordings had a seal resistance > 20 GΩ and a series resistance < 15 MΩ. Pulse generation, data acquisition, and analysis were performed using a PC equipped with a Digidata 1320 A/D interface in conjunction with Clampex 8 (Axon Instruments Inc.). The bath contained < 250 μl of saline and was continuously perfused at a rate of 2 ml/min using a gravity- driven perfusion system.
Identification of Correction Compounds
[00278] To determine the activity of correction compounds for increasing the density of functional ΔF508-CFTR in the plasma membrane, we used the above-described perforated-patch-recording techniques to measure the current density following 24-hr treatment with the correction compounds. To fully activate ΔF508-CFTR, 10 μM forskolin and 20 μM genistein were added to the cells. Under our recording conditions, the current density following 24-hr incubation at 27 °C was higher than that observed following 24-hr incubation at 37 0C. These results are consistent with the known effects of low-temperature incubation on the density of ΔF508-CFTR in the plasma membrane. To determine the effects of correction compounds on CFTR current density, the cells were incubated with 10 μM of the test compound for 24 hours at 370C and the current density was compared to the 27 0C and 37 0C controls (% activity). Prior to recording, the cells were washed 3X with extracellular recording medium to remove any remaining test compound. Preincubation with 10 μM of correction compounds significantly increased the cAMP- and genistein-dependent current compared to the 37 0C controls.
Identification of Potentiator Compounds
[00279] The ability of ΔF508-CFTR potentiators to increase the macroscopic
ΔF508-CFTR Cl' current (IΛFSOS) in NIH3T3 cells stably expressing ΔF508-CFTR was also investigated using perforated-patch-recording techniques. The potentiators identified from the optical assays evoked a dose-dependent increase in IΔFSOS with similar potency and efficacy observed in the optical assays. In all cells examined, the reversal potential before and during potentiator application was around -30 mV, which is the calculated Eci (-28 mV),
Solutions
Figure imgf000050_0001
iHO Cs-aspartate (90), CsCl (50), MgCl2 (1), HEPES (10), and
240 μg/ml amphotericin-B (pH adjusted to 7.35 with CsOH).
Extracellular solution (in mM): N-methyl-D-glucamine (NMDG)-Cl (150), MgCl2 (2),
CaCl2 (2), HEPES (10) (pH adjusted to 7.35 with HCl).
Cell Culture
[00280] NIH3T3 mouse fibroblasts stably expressing ΔF508-CFTR are used for whole-cell recordings. The cells are maintained at 37 0C in 5% CO2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ME, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For whole-cell recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 0C before use to test the activity of potentiators; and incubated with or without the correction compound at 37 0C for measuring the activity of correctors.
3. Single-channel recordings
[00281 ] The single-channel acti viti es of temperature-corrected ΔF 508-CFTR stably expressed in NIH3T3 cells and activities of potentiator compounds were observed using excised inside-out membrane patch. Briefly, voltage-clamp recordings of single-channel activity were performed at room temperature with an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc.). All recordings were acquired at a sampling frequency of 10 kHz and low-pass filtered at 400 Hz. Patch pipettes were fabricated from Corning Kovar Sealing #7052 glass (World Precision Instruments, Inc., Sarasota, FL) and had a resistance of 5 - 8 MΩ when filled with the extracellular solution. The ΔF508-CFTR was activated after excision, by adding 1 mM Mg-ATP, and 75 nM of the cAMP-dependent protein kinase, catalytic subunit (PKA; Promega Corp. Madison, WI). After channel activity stabilized, the patch was perfused using a gravity- driven microperfusion system. The inflow was placed adjacent to the patch, resulting in complete solution exchange within 1 - 2 sec. To maintain ΔF508-CFTR activity during the rapid perfusion, the nonspecific phosphatase inhibitor F" (10 mM NaF) was added to the bath solution. Under these recording conditions, channel activity remained constant throughout the duration of the patch recording (up to 60 min). Currents produced by positive charge moving from the intra- to extracellular solutions (anions moving in the opposite direction) are shown as positive currents. The pipette potential (Vp) was maintained at 80 mV.
[00282] Channel activity was analyzed from membrane patches containing < 2 active channels. The maximum number of simultaneous openings determined the number of icIivellchaArleli luSig'tii ftiiSdian experiment. To determine the single-channel current amplitude, the data recorded from 120 sec of ΔF508-CFTR activity was filtered "off-line" at 100 Hz and then used to construct all-point amplitude histograms that were fitted with multigaussian functions using Bio-Patch Analysis software (Bio-Logic Comp. France). The total microscopic current and open probability (P0) were determined from 120 sec of channel activity. The P0 was determined using the Bio-Patch software or from the relationship P0 = I/i(N), where I = mean current, i = single-channel current amplitude, and N = number of active channels in patch.
Solutions
Extracellular solution (in mM): NMDG (150), aspartic acid (150), CaCl2 (5), MgCl2 (2), and HEPES (10) (pH adjusted to 7.35 with Tris base). Intracellular solution (in mM): NMDG-Cl (150), MgCl2 (2), EGTA (5), TES (10), and Tris base (14) (pH adjusted to 7.35 with HCl).
Cell Culture
[00283] NIH3T3 mouse fibroblasts stably expressing ΔF508-CFTR are used for excised-membrane patch-clamp recordings. The cells are maintained at 37 0C in 5% CO2 and 90 % humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10 % fetal bovine serum, 1 X NEAA, β-ME, 1 X pen/strep, and 25 mM HEPES in 175 cm2 culture flasks. For single channel recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 0C before use.
[00284] Compounds of the invention are useful as modulators of ATP binding cassette transporters. Table 3 below illustrates the EC50 and relative efficacy of certain embodiments in Table 1.
[00285] In Table 3 below, the following meanings apply:
EC50: "+++" means <1 uM; "++" means between IuM to 5 uM; "+" means greater than 5 uM. Table 3
Figure imgf000051_0001
Figure imgf000051_0002
Figure imgf000052_0001
Figure imgf000052_0002
OTHER EMBODIMENTS
[00286] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

■IVHAT IS CLAIMED IS:
1. A method of modulating ABC transporter activity comprising the step of contacting said ABC transporter with a compound of formula (I):
Figure imgf000053_0001
I or a pharmaceutically acceptable salt thereof, wherein: Each R1 is independently R', halo, NO2, or CN; Each R2 is independently -XR';
Each X is independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of X are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NRS -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each R' is independently selected from hydrogen or an optionally substituted group selected from a Ci-8 aliphatic group, a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic or tricyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each R' group other than hydrogen is optionally substituted with 1-3 of-WRw;
Each m is independently 0-4;
Each R3 is independently H or a Ci-S aliphatic group optionally substituted with -X-RA and wherein up to two methylene units of the R3 aliphatic group may be replaced by -CO-, -CH2S-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR5-, -OCONR'-,
Figure imgf000054_0001
-S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR'SO2-, or -NR5SO2NR'-;
Each RA is independently R', halo, NO2, or CN;
Each R4 is a (cycloaliphatic)alkyl, (heterocycloaliphatic)alkyl, aralkyl, or heteroaralkyl wherein the alkyl portion of R4 is optionally substituted with R5 and wherein up to two methylene units of the alkyl portion of R4 may be replaced by -CO-, -CS-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-, and the cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl portions of R4 are optionally substituted with 1-3 of -WRW, or R4 is RB, or
R3 and R4 together with the nitrogen to which they are attached may form a 5 to 7 membered heterocycloaliphatic optionally substituted with 1 to 3 R';
RB is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally fused with an aryl or heteroaryl wherein RB attaches to the nitrogen atom via the cycloaliphatic or heterocycloaliphatic ring, and RB is optionally substituted with 1-3 of -WRW;
Each R5 is independently aryl, heteroaryl, Ci-8 aralkyl, or Ci-8 heteroaralkyl wherein the alkyl portion of R5 is optionally substituted with Rw and wherein up to two methylene units of the alkyl portion of R5 may be replaced by -CO-, -CS-, -CONR5-, -CONR'NR5-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR'NR5-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR5-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-, and the aryl or heteroaryl portions of R5 are optionally substituted with 1-3 of -WRW;
Each W is independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR5-, -CONR'NR5-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR5-, -OCONR5-, -NR'NR5-, -NR5NR5CO-, -NR5CO-, -S-, -SO-, -SO2-, -NR5-, -SO2NR5-, -NR5SO2-, or -NR5SO2NR5-; and
Each Rw is independently R', halo, NO2, CN, CF3, -O(Ci-4alkyl), -OCF3, or phenyl that is optionally substituted with 1-3 halo, haloalkyl, alkoxy, or aliphatic;
Provided that the compounds do not include, at the 5 position of the indole, the groups: -C(O)-(optionally substituted piperidinyl)-CH2-(optionally substituted phenyl), or -C(O)-(optionally substituted piperaziny I)-(C i_4alkyl)-(optionally substituted phenyl). Ψ. L !i Ty"nteffiy%c'coiiiiiyilim 1, wherein each R4 is C1-8 aralkyl or Ci-8 heteroaralkyl wherein the alkyl portion of R4 is optionally substituted with R5 and wherein up to two methylene units of the alkyl portion of R4 may be replaced by -CO-, -CS-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR1CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR5CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-, and the aryl or heteroaryl portions of R4 are optionally substituted with 1-3 of -WRW.
3. The method according to claim 1, wherein m is 1 or 2.
4. The method according to claim 1, wherein each occurrence of WRW is independently - C1-3alkyl, -O(C1-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, -SO2NH2, -COOR', -COR', -O(CH2)2N(R)(R'), -0(CH2)N(R)(R'), -CON(R)(R'), -(CH2)2OR'5 -(CH2)OR', optionally substituted monocyclic or bicyclic aromatic ring, optionally substituted arylsulfonyl, optionally substituted 5-membered heteroaryl ring, -N(R)(R'), -(CH2)2N(R)(R')5 or -(CH2)N(R)(R').
5. The method according to claim 1, wherein m is O.
6. The method according to claim 1, wherein m is 1.
7. The method according to claim 1, wherein m is 2.
8. The method according to claim 1, wherein R4 is (cycloaliphatic)alkyl, (heterocycloaliphatic)alkyl, aralkyl, or heteroaralkyl in which the alkyl portion of R4 is substituted with R5.
9. The method according to claim 8, wherein R5 is an optionally substituted C1-4 aliphatic group.
10. The method according to claim 8, wherein R4 is an aralkyl or a heteroaralkyl each optionally substituted with WRW.
11. The method according to claim 10, wherein W is a bond or is an optionally substituted Ci-6 alkylidene chain wherein one or two non-adjacent methylene units are optionally and independently replaced by -0-, -NR'-, -S-, -SO2-, -COO-, or -CO-.
12. The method according to claim 11, wherein Rw is R' or halo.
13. The method according to claim 12, wherein m is 1-4 and -WRW is selected from aliphatic, alkoxy, or alkylcarbonylamino.
14. The method according to claim 1, wherein R3 is H.
15. The method according to claim 1, wherein m is 1, 2, or 3, and each X is independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein one or two non-adjacent
Figure imgf000056_0001
-O-, -NR-, -S-, -SO2-, -COO-, or -CO-.
16. The method according to claim 15, wherein R1 is R' or halo.
17. The method according to claim 1, wherein m is 1-4, and each occurrence of -XR1 is independently -C]-3alkyl, -O(Ci-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, -SO2NH2, -COOR', -COR', -O(CH2)2N(R')(R'), -0(CH2)N(R')(R'), -C0N(R')(R'), -(CH2)2OR', -(CH2)OR', optionally substituted phenyl, -N(R')(R'), -(CH2)2N(R')(R!), or -(CH2)N(R')(RJ).
18. The method according to claim 16, wherein each R' is independently aliphatic.
19. A method of modulating ABC transporter activity comprising the step of contacting said ABC transporter with a compound of formula (Ilia):
Figure imgf000056_0002
Ilia or a pharmaceutically acceptable salt thereof, wherein: Each R1 is independently R', halo, NO2, or CN; Each R2 is independently -XR';
Each X is independently a bond or is an optionally substituted Ci.6 alkylidene chain wherein up to two methylene units of X are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR?-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR1SO2-, or -NR5SO2NR'-;
Each R' is independently selected from hydrogen or an optionally substituted group selected from a Ci-8 aliphatic group, a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic or tricyclic ring system having 0-5 heteroatoms independently selected from Sitfeg Jnf ol:||sA W!sύϊfil 3#^i Ocurrences of R are taken.together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each R' group other than hydrogen is optionally substituted with 1-3 of-WRw;
Each m is independently 0-4;
Each R >3 is independently H or a Ci-8 aliphatic group optionally substituted with -X-R and wherein up to two methylene units of the R3 aliphatic group may be replaced by -CO-, -CH2S-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR5NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each RA is independently R', halo, NO2, or CN;
Each W is independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR5-, -NR'NR'-, -NR5NR5CO-, -NR5CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each Rw is independently R', halo, NO2, CN, CF3, -O(C,.4alkyl), -OCF3, or phenyl that is optionally substituted with 1-3 halo, haloalkyl, alkoxy, or aliphatic;
Ring Zz is a cycloaliphatic or a heterocycloaliphatic, each of which is optionally substituted with 1-3 halo, haloalkyl, alkoxy, aliphatic, aryl, or heteroaryl, in which the aryl and heteroaryl are each optionally substituted with 1-3 of halo, alkoxy, haloalkyl, or aliphatic;
Each RE is independently halo, haloalkyl, alkoxy, or aliphatic; and Each d is independently O to 3.
20. A method of modulating ABC transporter activity comprising the step of contacting said ABC transporter with a compound of formula (II)
Figure imgf000058_0001
II or a pharmaceutically acceptable salt thereof, wherein: Each R1 is independently R', halo, NO2, or CN; Each R2 is independently -XR', halo, NO2, or CN;
Each R3 is independently H or a Ci .g aliphatic group optionally substituted with -X-RA and wherein up to two methylene units of the R3 aliphatic group may be replaced by -CO-, -CH2S-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR'CONR'-, -OCONR'-, -NR'NRS -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each RA is independently R', halo, NO2, or CN; Each m is independently 0-4;
Each X is independently a bond or is an optionally substituted Ci-C6 alkylidene chain wherein up to two methylene units of X are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each R' is independently selected from hydrogen or an optionally substituted group selected from a Ci-8 aliphatic group, a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic or tricyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms lnαependeήtlyielecled' froW'røirigfl, oxygen, or sulfur, each R' group other than hydrogen is optionally substituted with 1-3 of -WRW;
Each AA and AB is independently aryl, heteroaryl, or heterocycloaliphatic each optionally substituted with 1-3 of-WRw;
Each Yi and Y2 is independently a bond or is an optionally substituted Ci -6 alkylidene chain wherein up to two methylene units of the Ci-6 alkylidene chain are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2- , -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each W is independently a bond or is an optionally substituted C]-6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR5-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR5CONR'-, -OCONR5-, -NR1NR'-, -NR5NR5CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR5-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each Rw is independently R5, halo, NO2, CN, CF3, -O(Ci-4alkyl) or -OCF3; and
Each E is a independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of the Cj-6 alkylidene chain are optionally and independently replaced by -C(O)-, -CS-, -COCO-, CONR5-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2, -0-, -OCONR'-, -NR5NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-.
21. The method according to claim 20, wherein R2 is H.
22. The method according to claim 20, wherein one of Y1 and Y2 is Ci-C4 alkylidene chain wherein one methylene unit of the Ci-C4 alkylidene chain is optionally replaced by -CO-, -CS-, -COCO-, -CONR5-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR5-, -OCONR5-, -NR5NR5-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR5-.
23. The method according to claim 22, wherein a methylene unit of the Ci -C4 alkylidene chain is replaced by -CO-, -CS-, -0-, -S-, -SO-, -SO2-, or -NR5-.
24. The method according to claim 23, wherein a methylene unit of the Ci-C4 alkylidene chain is replaced by -0-, -S-, or -NR5-.
25. The method according to claim 24, wherein a methylene unit of the Ci-C4 alkylidene chain is replaced by -O- or -S-.
Figure imgf000060_0001
22, wherein one of Y1 and Y2 is Ci-C4 alkyl.
27. The method according to claim 20, wherein AA is an optionally substituted 6 membered aromatic ring having 1-3 heteroatoms or AA is an optionally substituted phenyl.
28. The method according to claim 27, wherein AA is phenyl.
29. The method according to claim 27, wherein AA is an optionally substituted pyridyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, or 1,2,4-triazinyl.
30. The method according to claim 20, wherein AA is an optionally substituted 5 -membered aromatic ring having 1-3 heteroatoms, wherein said heteroatom is nitrogen, oxygen, or sulfur.
31. The method according to claim 30, wherein AA is an optionally substituted 5-membered aromatic ring having 1-2 nitrogen atoms.
32. The method according to claim 1, wherein the compound is selected from:
Figure imgf000061_0001
Figure imgf000062_0001
33. A method of treating or reducing the severity of an ABC Transporter mediated disease comprising administering a compound as described in any one of claims 1, 19, and 20 to a mammal.
34. The method according to claim 33, wherein the ABC Transporter mediated disease is Cystic fibrosis, Hereditary emphysema, Hereditary hemochromatosis, Coagulation-Fibrinolysis deficiencies, such as Protein C deficiency, Type 1 hereditary angioedema, Familial hypercholesterolemia, Type 1 chylomicronemia, Abetalipoproteinemia, I-cell disease/Pseudo- Hurler, Mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, Polyendocrinopathy/Hyperinsulemia, Diabetes mellitus, Laron dwarfism, Myleoperoxidase deficiency, Primary hypoparathyroidism, Melanoma, Glycanosis CDG type 1, Hereditary emphysema, Congenital hyperthyroidism, Osteogenesis imperfecta, Hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), Neurophyseal DI, Neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Progressive supranuclear plasy, Pick's disease, Huntington's disease, Spinocerebullar ataxia type I, Spinal and bulbar muscular atrophy, Dentatorubal pallidoluysian, Myotonic dystrophy, Hereditary Creutzfeldt- Jakob disease, Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, and Sjogren's disease.
35. A compound of formula (II) :
Figure imgf000063_0001
π or a pharmaceutically acceptable salt thereof, wherein: Each R1 is independently R', halo, NO2, or CN; Each R2 is independently -XR', halo, NO2, or CN;
Each R3 is independently H or a C1-S aliphatic group optionally substituted with -X-RA and wherein up to two methylene units of the R3 aliphatic group may be replaced by -CO-, -CH2S-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each m is independently 0-4;
Each X is independently a bond or is an optionally substituted CpC6 alkylidene chain wherein up to two methylene units of X are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR5-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR5-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR5-;
Each R5 is independently selected from hydrogen or an optionally substituted group selected from a Cj-8 aliphatic group, a 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bridged bicyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic or tricyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each R5 group other than hydrogen is optionally substituted with 1-3 of -WRW; P C T StfppfaiaaS i'Salo, NO2, or CN;
Each AA and AB is independently aryl, heteroaryl, or heterocycloaliphatic each optionally substituted with 1-3 of -WRW;
Each Yi and Y2 is independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of the Ci -6 alkylidene chain are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR5CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR'-;
Each W is independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by -CO-, -CS-, -COCO-, -CONR5-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -O-, -NR5CONR5-, -OCONR5-, -NR5NR'-, -NR'NR'CO-, -NR5CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR'-, -NR5SO2-, or -NR5SO2NR5-;
Each Rw is independently R', halo, NO2, CN, CF3, -O(CMalkyl) or -OCF3; and
Each E is an independently a bond or is an optionally substituted Ci-6 alkylidene chain wherein up to two methylene units of the Ct-6 alkylidene chain are optionally and independently replaced by -C(O)-, -CS-, -COCO-, CONR5-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2, -0-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR'CO-, -S-, -SO-, SO2-, -NR'-, -SO2NR5-, -NR5SO2-, -NR5SO2NR'-; provided that the compound is not N-[l-[(3,5-difluorophenyl)methyl]-3-[[(3- ethylphenyl)methyl]amino]-2-hydroxypropyl]-l-methyl-α-oxo-lH-indole-3-acetamide, 2-(1H- indol-3-yl)-N-(2-morpholino-l-phenylethyl)-2-oxoacetamide, or N-(l,3-bis(benzylthio)ρropan- 2-yl)-2-(lH-indol-3-yl)-2-oxoacetamide.
36. The compound according to claim 35, wherein R2 is H.
37. The compound according to claim 36, wherein one of Y1 and Y2 is Cj-C4 alkylidene chain wherein one methylene unit of the Ci-C4 alkylidene chain is optionally replaced by -CO-, -CS-, -COCO-, -CONR'-, -CONR'NR'-, -CO2-, -OCO-, -NR5CO2-, -0-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'NR'CO-, -NR5CO-, -S-, -SO-, -SO2-, -NR'-, -SO2NR5-, -NR5SO2-, or -NR5SO2NR'-.
38. The compound according to claim 37, wherein a methylene unit of the C1-C4 alkylidene chain is replaced by -CO-, -CS-, -0-, -S-, -SO-, -SO2-, or -NR5-. Oslaim 38, wherein a methylene unit of the Cj-C4 alkylidene chain is replaced by -0-, -S-, or -NR'-.
40. The compound according to claim 39, wherein a methylene unit of the Ci-C4 alkylidene chain is replaced by -O- or -S-.
41. The compound according to claim 40, wherein one of Y1 and Y2 is Ci-C4 alkylene chain.
42. The compound according to claim 35, wherein AA is an optionally substituted 6 membered aromatic ring having 1 -3 heteroatoms or AA is an optionally substituted phenyl.
43. The compound according to claim 35, wherein AA is phenyl.
44. The compound according to claim 35, wherein AA is an optionally substituted pyridyl, pyrimidinyl, pyrazinyl or triazinyl.
45. The compound according to claim 35, wherein AA is an optionally substituted 5- membered aromatic ring having 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur.
46. The compound according to claim 35, wherein m is 1, 2, or 3, and each X is independently a bond or an optionally substituted Ci-6 alkylidene chain wherein one or two non- adjacent methylene units are optionally and independently replaced by -O-, -NR-, -S-, -SO2-, -COO-, or -CO-.
47. The compound according to claim 46, wherein R1 is R' or halo.
48. The compound according to claim 35, wherein m is 1, 2, or 3, and each occurrence of - XR1 is independently halo, -Ci-3alkyl, -O(Ci-3alkyl), -CF3, -OCF3, -SCF3, -F, -Cl, -Br, -SO2NH2, -COOR', -COR', -O(CH2)2N(R)(R'), -0(CH2)N(R)(R'), -CON(R)(R'), -(CH2)2OR', -(CH2)OR', optionally substituted monocyclic or bicyclic aromatic ring, optionally substituted arylsulfonyl, optionally substituted 5-membered heteroaryl ring, -N(R)(R'), -(CH2)2N(R)(R'), or -(CH2)N(R)(R').
49. The compound according to claim 35, wherein R3 is H.
50. A compound selected from:
Figure imgf000066_0001
51. A pharmaceutical composition comprising: (i) a compound according to claim 35; and (ii) a pharmaceutically acceptable carrier.
52. The composition according to claim 51, optionally further comprising an additional agent selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an antiinflammatory agent, CFTR modulator, or a nutritional agent.
53. A method of increasing the number of functional ABC transporters in a membrane of a cell, comprising the step of contacting said cell with a compound according to claim 35.
54. The method according to claim 53, wherein the ABC transporter is CFTR.
55. A kit for use in measuring the activity of a ABC transporter or a fragment thereof in a biological sample in vitro or in vivo, comprising:
(i) a composition comprising a compound according to any of claims 1, 19, 20, and 35;
(ii) instructions for:
Figure imgf000067_0001
with the biolo§ical samPle; b) measuring activity of said ABC transporter or a fragment thereof. 56. The kit according to claim 55, wherein the kit is used to measure the density of CFTR.
PCT/US2006/039220 2005-10-06 2006-10-06 Modulators of atp-binding cassette transporters WO2007044560A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002624683A CA2624683A1 (en) 2005-10-06 2006-10-06 Modulators of atp-binding cassette transporters
EP06825588A EP1933831A2 (en) 2005-10-06 2006-10-06 Modulators of atp-binding cassette transporters
JP2008534730A JP2009511494A (en) 2005-10-06 2006-10-06 ATP-binding cassette transporter modulator
AU2006302371A AU2006302371A1 (en) 2005-10-06 2006-10-06 Modulators of ATP-Binding cassette transporters
IL190570A IL190570A0 (en) 2005-10-06 2008-04-02 Modulators of atp-binding cassette transporters
NO20082082A NO20082082L (en) 2005-10-06 2008-05-05 Modulators for ATP binding cassette transporters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72473605P 2005-10-06 2005-10-06
US60/724,736 2005-10-06

Publications (2)

Publication Number Publication Date
WO2007044560A2 true WO2007044560A2 (en) 2007-04-19
WO2007044560A3 WO2007044560A3 (en) 2007-06-14

Family

ID=37770668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/039220 WO2007044560A2 (en) 2005-10-06 2006-10-06 Modulators of atp-binding cassette transporters

Country Status (12)

Country Link
US (2) US8314256B2 (en)
EP (1) EP1933831A2 (en)
JP (1) JP2009511494A (en)
KR (1) KR20080064971A (en)
CN (1) CN101312722A (en)
AU (1) AU2006302371A1 (en)
CA (1) CA2624683A1 (en)
IL (1) IL190570A0 (en)
NO (1) NO20082082L (en)
RU (1) RU2008118001A (en)
WO (1) WO2007044560A2 (en)
ZA (1) ZA200803701B (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073623A2 (en) * 2006-11-02 2008-06-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
WO2009133387A1 (en) * 2008-04-29 2009-11-05 Lectus Therapeutics Limited Indole- 3 -glyoxylamide derivatives for use as calcium ion channel modulators
WO2010001179A2 (en) * 2008-07-03 2010-01-07 Lectus Therapeutics Limited Calcium ion channel modulators & uses thereof
WO2010035032A1 (en) * 2008-09-25 2010-04-01 Lectus Therapeutics Limited Calcium ion channel modulators & uses thereof
WO2011119984A1 (en) 2010-03-25 2011-09-29 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011127290A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2011133751A2 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
WO2012027247A2 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
WO2012170061A1 (en) 2011-06-08 2012-12-13 Vertex Pharmaceuticals Incorporated Formulations of (r)-1-(2,2-diflurobenzo[d][1,3] dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methyl propan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
EP2578571A1 (en) 2007-11-16 2013-04-10 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-binding cassette transporters
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP2615085A1 (en) 2008-03-31 2013-07-17 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RU2512682C2 (en) * 2008-11-06 2014-04-10 Вертекс Фармасьютикалз Инкорпорейтед Modulators of atp-binding cassette transporters
WO2014071122A1 (en) 2012-11-02 2014-05-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
WO2014081821A2 (en) * 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small Molecule Bicyclic and Tricyclic CFTR Correctors
WO2015160787A1 (en) 2014-04-15 2015-10-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US9221840B2 (en) 2011-05-17 2015-12-29 Discoverybiomed Inc. Treating protein folding disorders with small molecule CFTR correctors
WO2016057572A1 (en) 2014-10-06 2016-04-14 Mark Thomas Miller Modulators of cystic fibrosis transmembrane conductance regulator
EP3170818A1 (en) 2007-12-07 2017-05-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US9676779B2 (en) 2012-11-20 2017-06-13 Discoverybiomed, Inc. Small molecule CFTR correctors
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc Modulation of protein methylation and phosphoprotein phosphate
RU2006111093A (en) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) MODULATORS OF ATR-BINDING CASSETTE TRANSPORTERS
NZ547220A (en) * 2003-11-14 2009-12-24 Vertex Pharma Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
BR122018075478B8 (en) 2004-06-24 2023-10-31 Vertex Pharma atp link cassette carrier modulators
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
JP5143738B2 (en) 2005-08-11 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of cystic fibrosis membrane conductance regulator
ES2439736T3 (en) 2005-11-08 2014-01-24 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP binding cassette transporters
HUE049976T2 (en) 2005-12-28 2020-11-30 Vertex Pharma Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2856037C (en) * 2005-12-28 2017-03-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CN104447716A (en) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Modulators of CFTR
WO2009038913A2 (en) 2007-08-24 2009-03-26 Vertex Pharmaceuticals Incorporated Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
CA2989620C (en) * 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
WO2009076141A2 (en) * 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2271622B1 (en) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR Modulators
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
CN102164587A (en) * 2008-09-29 2011-08-24 沃泰克斯药物股份有限公司 Dosage units of 3-(6-(1-(2,2-difluorobenzo [D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EA018891B1 (en) 2008-10-23 2013-11-29 Вертекс Фармасьютикалз, Инкорпорейтед Modulators of cystic fibrosis transmembrane conductance regulator
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
CN109966264A (en) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 Pharmaceutical composition and its application
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN107250113B (en) 2014-10-07 2019-03-29 弗特克斯药品有限公司 Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
JP6494757B2 (en) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Process for high-throughput high performance liquid chromatography

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838A1 (en) * 1998-04-02 1999-10-14 Asta Medica Ag Indolyl-3-glyoxylic acid derivatives with anti-tumor effects
WO2001055107A2 (en) * 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
US20030181482A1 (en) * 2001-12-06 2003-09-25 Chiung-Tong Chen Novel compounds and methods of use thereof
US20040009990A1 (en) * 2001-11-09 2004-01-15 Higgins Linda S. Method to treat cystic fibrosis
WO2004022523A2 (en) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109559A1 (en) * 2001-07-11 2003-06-12 Andrea Gailunas N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838A1 (en) * 1998-04-02 1999-10-14 Asta Medica Ag Indolyl-3-glyoxylic acid derivatives with anti-tumor effects
WO2001055107A2 (en) * 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
US20040009990A1 (en) * 2001-11-09 2004-01-15 Higgins Linda S. Method to treat cystic fibrosis
US20030181482A1 (en) * 2001-12-06 2003-09-25 Chiung-Tong Chen Novel compounds and methods of use thereof
WO2004022523A2 (en) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"ANNUAL REVIEW 2002: RESPIRATORY DRUGS" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 27, no. 2, 1 December 2002 (2002-12-01), pages 1195-1232, XP002397174 ISSN: 0377-8282 *
GOTTESMAN M M ET AL: "OVERVIEW: ABC TRANSPORTERS AND HUMAN DISEASE" JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, PLENUM PUBLISHING, NEW YORK, NY, US, vol. 33, no. 6, December 2001 (2001-12), pages 453-458, XP009032020 ISSN: 0145-479X *
KUMAR, ASHOK ET AL: "Synthesis and biological activity of 2-substituted-3- (aminoethyl)indoles" JOURNAL OF HETEROCYCLIC CHEMISTRY , 18(6), 1269-71 CODEN: JHTCAD; ISSN: 0022-152X, 1981, XP002423939 *
VAN DER DEEN MARGARETHA ET AL: "ATP-binding cassette (ABC) transporters in normal and pathological lung" RESPIRATORY RESEARCH, BIOMED CENTRAL LTD., LONDON, GB, vol. 6, no. 1, 20 June 2005 (2005-06-20), page 59, XP021000149 ISSN: 1465-9921 *

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975061B2 (en) 2006-04-07 2021-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11639347B2 (en) 2006-04-07 2023-05-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10987348B2 (en) 2006-04-07 2021-04-27 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10239867B2 (en) 2006-04-07 2019-03-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2008073623A3 (en) * 2006-11-02 2009-04-09 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
WO2008073623A2 (en) * 2006-11-02 2008-06-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
EP2578571A1 (en) 2007-11-16 2013-04-10 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-binding cassette transporters
EP3012250A1 (en) 2007-11-16 2016-04-27 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
EP3170818A1 (en) 2007-12-07 2017-05-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP3683218A1 (en) 2007-12-07 2020-07-22 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2615085A1 (en) 2008-03-31 2013-07-17 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
EP2980077A1 (en) 2008-03-31 2016-02-03 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
WO2009133387A1 (en) * 2008-04-29 2009-11-05 Lectus Therapeutics Limited Indole- 3 -glyoxylamide derivatives for use as calcium ion channel modulators
WO2010001179A3 (en) * 2008-07-03 2010-11-11 Lectus Therapeutics Limited Calcium ion channel modulators & uses thereof
WO2010001179A2 (en) * 2008-07-03 2010-01-07 Lectus Therapeutics Limited Calcium ion channel modulators & uses thereof
WO2010035032A1 (en) * 2008-09-25 2010-04-01 Lectus Therapeutics Limited Calcium ion channel modulators & uses thereof
RU2512682C2 (en) * 2008-11-06 2014-04-10 Вертекс Фармасьютикалз Инкорпорейтед Modulators of atp-binding cassette transporters
EP2826776A1 (en) 2010-03-25 2015-01-21 Vertex Pharmaceuticals Incorporated Solid amorphous form of (R)-1(2,2-difluorobenzo(D)(1,3)dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)-cyclopropanecarboxamide
EP4253381A2 (en) 2010-03-25 2023-10-04 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]d ioxol-5-yl)-n-(1-(2,3-dihydroxyp ropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1h-indol- 5-yl) cyclopropanecarboxamide
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
WO2011119984A1 (en) 2010-03-25 2011-09-29 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
EP3181561A1 (en) 2010-03-25 2017-06-21 Vertex Pharmaceuticals Incorporated Synthetic intermediate of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
US11578062B2 (en) 2010-03-25 2023-02-14 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP3835297A1 (en) 2010-03-25 2021-06-16 Vertex Pharmaceuticals Incorporated Synthesis and intermediates of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
US10906891B2 (en) 2010-03-25 2021-02-02 Vertex Pharmaceuticals Incoporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP3150198A1 (en) 2010-04-07 2017-04-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EP4005559A1 (en) 2010-04-07 2022-06-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011127290A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2011127241A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
WO2011133751A2 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
EP3381899A1 (en) 2010-04-22 2018-10-03 Vertex Pharmaceuticals Incorporated Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
WO2012027247A2 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
US9221840B2 (en) 2011-05-17 2015-12-29 Discoverybiomed Inc. Treating protein folding disorders with small molecule CFTR correctors
WO2012170061A1 (en) 2011-06-08 2012-12-13 Vertex Pharmaceuticals Incorporated Formulations of (r)-1-(2,2-diflurobenzo[d][1,3] dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methyl propan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
WO2014071122A1 (en) 2012-11-02 2014-05-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
EP3470063A1 (en) 2012-11-02 2019-04-17 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
US20150307503A1 (en) * 2012-11-20 2015-10-29 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic cftr correctors
US9546176B2 (en) 2012-11-20 2017-01-17 Discoverybiomed, Inc. Small molecule bicyclic and tricyclic CFTR correctors
WO2014081821A3 (en) * 2012-11-20 2014-08-28 Discoverybiomed, Inc. Small Molecule Bicyclic and Tricyclic CFTR Correctors
WO2014081821A2 (en) * 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small Molecule Bicyclic and Tricyclic CFTR Correctors
US9676779B2 (en) 2012-11-20 2017-06-13 Discoverybiomed, Inc. Small molecule CFTR correctors
US10980746B2 (en) 2014-04-15 2021-04-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3424534A1 (en) 2014-04-15 2019-01-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2015160787A1 (en) 2014-04-15 2015-10-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3925607A1 (en) 2014-04-15 2021-12-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP4223294A1 (en) 2014-04-15 2023-08-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US11951212B2 (en) 2014-04-15 2024-04-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2016057572A1 (en) 2014-10-06 2016-04-14 Mark Thomas Miller Modulators of cystic fibrosis transmembrane conductance regulator

Also Published As

Publication number Publication date
US20070238775A1 (en) 2007-10-11
US8853254B2 (en) 2014-10-07
JP2009511494A (en) 2009-03-19
WO2007044560A3 (en) 2007-06-14
ZA200803701B (en) 2009-08-26
NO20082082L (en) 2008-06-25
RU2008118001A (en) 2009-11-20
CA2624683A1 (en) 2007-04-19
IL190570A0 (en) 2009-08-03
US8314256B2 (en) 2012-11-20
US20130184276A1 (en) 2013-07-18
CN101312722A (en) 2008-11-26
EP1933831A2 (en) 2008-06-25
KR20080064971A (en) 2008-07-10
AU2006302371A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
US8853254B2 (en) Modulators of ATP-binding cassette transporters
EP2363128B1 (en) Indole modulators of ATP-binding cassette transporters
JP5885359B2 (en) Isoquinoline regulator of ATP binding cassette transporter
US8012999B2 (en) Modulators of CFTR
US8232302B2 (en) Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters
EP1891018B1 (en) Modulators of atp-binding cassette transporters
AU2008363828B2 (en) Modulators of ATP-binding cassette transporters
WO2007075901A2 (en) Quinolin- 4 - one derivatives as modulators of abc transporters
WO2009023509A2 (en) Therapeutic combinations useful in treating cftr related diseases
MX2008004673A (en) Modulators of atp-binding cassette transporters

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680044039.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006825588

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 190570

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2624683

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008534730

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004673

Country of ref document: MX

Ref document number: 1399/KOLNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006302371

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 567571

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008118001

Country of ref document: RU

Ref document number: 1020087010913

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006302371

Country of ref document: AU

Date of ref document: 20061006

Kind code of ref document: A